,Name,url,Sector,Industry,Employees,Description,Executive1,Executive2,Executive3,Executive4,Executive5
ABUS,Arbutus Biopharma Corporation,http://www.tekmirapharm.com,Healthcare,Biotechnology,122,"Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companys lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.","{'name': 'Dr. Mark Joseph Murray Ph.D.', 'title': 'CEO, Pres & Exec. Director', 'pay': '794.78k', 'exercised': 'N/A', 'age': '68'}","{'name': 'Mr. Bruce G. Cousins C.A., CPA', 'title': 'Exec. VP of Fin. & CFO', 'pay': '490.31k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Peter  Lutwyche Ph.D.', 'title': 'Chief Technology Officer', 'pay': '400.22k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Michael J. Sofia Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '464k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Elizabeth  Howard Ph.D., J.D.', 'title': 'Exec. VP & Gen. Counsel', 'pay': '363.3k', 'exercised': 'N/A', 'age': '63'}"
ACAD,ACADIA Pharmaceuticals Inc.,http://www.acadia-pharm.com,N/A,N/A,N/A,"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.","{'name': 'Mr. Stephen R. Davis J.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.13M', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Todd S. Young', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '409.1k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Glenn F. Baity', 'title': 'Exec. VP, Gen. Counsel and Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. Srdjan R. Stankovic M.D., M.S.P.H.', 'title': 'Head of R&D and Exec. VP', 'pay': '709.79k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. James A. Nash', 'title': 'Sr. VP of Technology Devel. & Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '66'}"
ACHN,"Achillion Pharmaceuticals, Inc.",http://www.achillion.com,Healthcare,Biotechnology,81,"Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.","{'name': 'Dr. Milind S. Deshpande Ph.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '816.45k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Ms. Mary Kay Fenton', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '481.24k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Joseph  Truitt', 'title': 'Chief Operating Officer', 'pay': '491.44k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. David  Apelian', 'title': 'Former Exec. VP & Chief Medical Officer', 'pay': '658.21k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Glenn  Schulman', 'title': 'Exec. Director of Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ACOR,"Acorda Therapeutics, Inc.",http://www.acorda.com,Healthcare,Biotechnology,597,"Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.","{'name': 'Dr. Ron  Cohen', 'title': 'Founder, Chief Exec. Officer, Pres and Director', 'pay': '1.34M', 'exercised': '1.03M', 'age': '62'}","{'name': 'Mr. David  Lawrence M.B.A.', 'title': 'Chief of Bus. Operations and Principal Accounting Officer', 'pay': '623.05k', 'exercised': '8.29k', 'age': '60'}","{'name': 'Ms. Jane  Wasman J.D.', 'title': 'Pres of International, Gen. Counsel and Corp. Sec.', 'pay': '900.13k', 'exercised': '52.13k', 'age': '62'}","{'name': 'Mr. Andrew Asa Hindman M.B.A', 'title': 'Chief Bus. Devel. Officer', 'pay': '707.83k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Dr. Burkhard  Blank M.D.', 'title': 'Chief Medical Officer', 'pay': '1.09M', 'exercised': 'N/A', 'age': '63'}"
ACRS,"Aclaris Therapeutics, Inc.",http://www.aclaristx.com,N/A,N/A,N/A,"Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts. In addition, it is developing JAK inhibitors, including ATI-50001 that has completed Phase I clinical trial for the oral treatment of alopecia totalis and alopecia universalis; and ATI-50002, which has completed Phase I clinical trial for the topical treatment of patchy autoimmune dermatologic condition. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.","{'name': 'Dr. Neal  Walker D.O.', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Director', 'pay': '704.1k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Christopher V. Powala', 'title': 'Co-Founder and Chief Operating Officer', 'pay': '477.47k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Ms. Kamil  Ali-Jackson J.D.', 'title': 'Co-Founder, Chief Legal Officer, Chief Compliance Officer and Sec.', 'pay': '460.52k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Stuart D. Shanler M.D.', 'title': 'Co-Founder and Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Frank  Ruffo', 'title': 'Co-Founder and Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}"
ADAP,Adaptimmune Therapeutics plc,http://www.adaptimmune.com,N/A,N/A,N/A,"Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The companys lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma. It is also developing MAGE A-10 peptide that is in Phase I/II clinical trials to treat urothelial (bladder), melanoma, and head and neck cancers, as well as NSCLC; AFP SPEAR T-cell therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma; and MAGE-A4 to treat urothelial (bladder), melanoma, head and neck, esophageal and gastric, and ovarian cancer, as well as NSCLC. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a collaboration agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.","{'name': 'Mr. James Julian Noble', 'title': 'Chief Exec. Officer and Director', 'pay': '505.96k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Adrian  Rawcliffe', 'title': 'Chief Financial Officer', 'pay': '586.71k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Rafael  Amado M.D.', 'title': 'Chief Medical Officer', 'pay': '566.39k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Bent  Jakobsen Ph.D.', 'title': 'Scientific Co-Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Helen Katrina Tayton-Martin Ph.D., MBA', 'title': 'Co-Founder and Chief Bus. Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}"
ADMS,"Adamas Pharmaceuticals, Inc.",http://www.adamaspharma.com,N/A,N/A,N/A,"Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The companys product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinsons disease. Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimers disease. The companys products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed first Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.","{'name': 'Dr. Gregory T. Went Ph.D.', 'title': 'Co-Founder, Chairman & CEO', 'pay': '700.69k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Ms. Jennifer J. Rhodes', 'title': 'Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec.', 'pay': '328.53k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Dr. Rajiv  Patni M.D.', 'title': 'Chief Medical Officer', 'pay': '551.4k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Alfred G. Merriweather', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}","{'name': 'Mr. Richard A. King', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}"
ADRO,"Aduro BioTech, Inc.",http://www.aduro.com,Healthcare,Biotechnology,143,"Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companys products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.","{'name': 'Mr. Stephen T. Isaacs', 'title': 'Chairman, Pres & CEO', 'pay': '823.7k', 'exercised': 'N/A', 'age': '69'}","{'name': 'Mr. Blaine E. Templeman', 'title': 'Exec. VP, Gen. Counsel and Sec.', 'pay': '698.68k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Natalie R. Sacks M.D.', 'title': 'Chief Medical Officer', 'pay': '284.14k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Ms. Jennifer  Lew', 'title': 'Sr. VP of Fin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Gregory W. Schafer MBA', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '54'}"
AERI,"Aerie Pharmaceuticals, Inc.",http://www.aeriepharma.com,N/A,N/A,N/A,"Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research and development agreement with Royal DSM NV. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.","{'name': 'Dr. Vincente J. Anido Jr., Ph.D.', 'title': 'Chairman & CEO', 'pay': '878.43k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. Thomas A. Mitro', 'title': 'Pres & COO', 'pay': '594.65k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Richard J. Rubino CPA', 'title': 'CFO & Sec.', 'pay': '567.3k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. Casey C. Kopczynski Ph.D.', 'title': 'Co-Founder & Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}","{'name': 'Ms. Jessica  Crespo CPA', 'title': 'Director of Accounting', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
AGIO,"Agios Pharmaceuticals, Inc.",http://www.agios.com,N/A,N/A,N/A,"Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.","{'name': 'Dr. David P. Schenkein M.D.', 'title': 'CEO, Pres & Director', 'pay': '918.73k', 'exercised': '2.36M', 'age': '61'}","{'name': 'Dr. Lewis Clayton Cantley Ph.D.', 'title': 'Co-Founder, Director & Member of Scientific Advisory Board', 'pay': '48.12k', 'exercised': 'N/A', 'age': '69'}","{'name': 'Mr. Andrew  Hirsch', 'title': 'Chief Financial Officer', 'pay': '303.37k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. Scott A. Biller Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '593.87k', 'exercised': '5.01M', 'age': '62'}","{'name': 'Dr. Christopher  Bowden M.D.', 'title': 'Chief Medical Officer', 'pay': '619.63k', 'exercised': 'N/A', 'age': '57'}"
AIMT,"Aimmune Therapeutics, Inc.",http://www.aimmune.com,N/A,N/A,N/A,"Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.","{'name': 'Dr. Stephen George Dilly M.B.B.S, Ph.D.', 'title': 'CEO, Pres & Director', 'pay': '660k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Jeffrey H. Knapp', 'title': 'Chief Operating Officer', 'pay': '539.25k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Daniel C. Adelman M.D.', 'title': 'Chief Medical Officer', 'pay': '293.07k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Eric H. Bjerkholt', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Laura  Hansen Ph.D.', 'title': 'VP of Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
AKAO,"Achaogen, Inc.",http://www.achaogen.com,N/A,N/A,N/A,"Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.","{'name': 'Dr. Kenneth J. Hillan M.B., Ch.B.', 'title': 'CEO & Director', 'pay': '771.6k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Blake  Wise', 'title': 'Pres & COO', 'pay': '644k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. Floyd E. Romesberg Ph.D.', 'title': 'Principal Scientific Founder and Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Nathaniel E. David A.B., Ph.D.', 'title': 'Principal Entrepreneurial Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Tobin C. Schilke', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '43'}"
AKBA,"Akebia Therapeutics, Inc.",http://www.akebia.com,N/A,N/A,N/A,"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. John P. Butler MBA', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '777.69k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Jason A. Amello', 'title': 'Chief Financial Officer, Sr. VP and Treasurer', 'pay': '478.03k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Bradley  J. Maroni M.D.', 'title': 'Medical Advisor', 'pay': '574.77k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Ms. Theresa  McNeely', 'title': 'Sr. VP - Corp. Communications and Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '54'}","{'name': 'Ms. Nicole R. Hadas J.D.', 'title': 'Sr. VP, Gen. Counsel and Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '45'}"
AKCA,"Akcea Therapeutics, Inc.",http://www.akceatx.com,N/A,N/A,N/A,"Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.","{'name': 'Ms. Paula  Soteropoulos', 'title': 'Pres, CEO & Director', 'pay': '778.55k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Jeffrey M. Goldberg', 'title': 'Chief Operating Officer', 'pay': '565.66k', 'exercised': 'N/A', 'age': '45'}","{'name': ""Dr. Louis St. Laurence O'Dea MB, BCh, BAO, FRCP(C)"", 'title': 'Chief Medical Officer & Head of Regulatory Affairs', 'pay': '708.61k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Mr. Michael F. MacLean', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'D. Wade Walke Ph.D.', 'title': 'VP of Corp. Communications & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ALDR,"Alder Biopharmaceuticals, Inc.",http://www.alderbio.com,Healthcare,Biotechnology,176,"Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The companys lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis. In addition, the company has preclinical programs in the discovery phase for various indications. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.","{'name': 'Dr. Randall C. Schatzman Ph.D.', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Director', 'pay': '833.62k', 'exercised': '3.04M', 'age': '63'}","{'name': 'Dr. John A. Latham Ph.D.', 'title': 'Co-Founder and Chief Scientific Officer', 'pay': '603.97k', 'exercised': '3.28M', 'age': '58'}","{'name': 'Mr. Larry K. Benedict', 'title': 'Principal Accounting Officer and Exec. VP', 'pay': '392.27k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Timothy M. Whitaker M.D.', 'title': 'Chief Medical Officer', 'pay': '385.42k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Ms. Elisabeth A. Sandoval M.B.A', 'title': 'Chief Commercial Officer', 'pay': '222.66k', 'exercised': 'N/A', 'age': '56'}"
ALKS,Alkermes plc,http://www.alkermes.com,N/A,N/A,N/A,"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The companys marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.","{'name': 'Mr. Richard F. Pops', 'title': 'Chairman and Chief Exec. Officer', 'pay': '2.57M', 'exercised': '6.43M', 'age': '56'}","{'name': 'Mr. Shane Martin Cooke', 'title': 'Pres', 'pay': '1.31M', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Floyd E. Bloom M.D.', 'title': 'Co-Founder and Director', 'pay': '85.5k', 'exercised': 'N/A', 'age': '81'}","{'name': 'Mr. James M. Frates', 'title': 'Chief Financial Officer, Sr. VP and Treasurer', 'pay': '876.25k', 'exercised': '2.57M', 'age': '51'}","{'name': 'Ms. Kathryn L. Biberstein', 'title': 'Chief Admin. Officer, Chief Compliance Officer, Chief Risk Officer, EVP and Sec.', 'pay': '1.08M', 'exercised': '1.66M', 'age': '59'}"
ALNY,"Alnylam Pharmaceuticals, Inc.",http://www.alnylam.com,N/A,N/A,N/A,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The companys clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.","{'name': 'Dr. John M. Maraganore M.D., Ph.D.', 'title': 'CEO & Exec. Director', 'pay': '1.12M', 'exercised': '4.86M', 'age': '54'}","{'name': 'Mr. Barry E. Greene', 'title': 'Pres', 'pay': '775.15k', 'exercised': '1.95M', 'age': '54'}","{'name': 'Mr. John K. Clarke', 'title': 'Founder & Director', 'pay': '60k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Dr. Phillip A. Sharp Ph.D.', 'title': 'Co-Founder, Director & Member of the Scientific Advisory Board', 'pay': '90k', 'exercised': 'N/A', 'age': '72'}","{'name': 'Dr. Yvonne L.  Greenstreet MBChB, MBA', 'title': 'COO & Exec. VP', 'pay': '340.61k', 'exercised': 'N/A', 'age': '54'}"
ALXN,"Alexion Pharmaceuticals, Inc.",http://www.alexion.com,Healthcare,Biotechnology,"3,121","Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.","{'name': ""Ms. Julie  O'Neill MBA"", 'title': 'Exec. VP of Global Operations', 'pay': '1.08M', 'exercised': 'N/A', 'age': '63'}","{'name': 'Dr. Ludwig N. Hantson Ph.D.', 'title': 'CEO & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Paul J. Clancy M.B.A.', 'title': 'Exec. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Daniel A. Bazarko CPA', 'title': 'Chief Accounting Officer and Sr. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Elena  Ridloff CFA', 'title': 'VP of Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
AMAG,"AMAG Pharmaceuticals, Inc.",http://www.amagpharma.com,Healthcare,Diagnostic Substances,545,"AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womens health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.","{'name': 'Dr. William K. Heiden', 'title': 'CEO & Director', 'pay': '1.18M', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Edward H. Myles MBA', 'title': 'Exec. VP & CFO', 'pay': '434.9k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Joseph D. Vittiglio Esq.', 'title': 'Exec. VP of Quality, Gen. Counsel & Sec.', 'pay': '528.06k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Julie  Krop M.D.', 'title': 'Exec. VP & Chief Medical Officer', 'pay': '567.37k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Nicholas  Grund', 'title': 'Exec. VP & Chief Commercial Officer', 'pay': '772.39k', 'exercised': 'N/A', 'age': '48'}"
AMGN,Amgen Inc.,http://www.amgen.com,Healthcare,Biotechnology,"19,200","Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The companys products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The companys marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; Array BioPharma Inc.; Syngene International Limited; and CytomX Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.","{'name': 'Mr. Robert A. Bradway', 'title': 'Chairman and Chief Exec. Officer', 'pay': '5.85M', 'exercised': '8.19M', 'age': '55'}","{'name': 'Mr. David W. Meline', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '2.72M', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Jonathan P. Graham', 'title': 'Sr. VP, Gen. Counsel & Sec.', 'pay': '4.12M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Sean E. Harper M.D.', 'title': 'Exec. VP of R&D', 'pay': '2.71M', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Anthony C. Hooper', 'title': 'Exec. VP of Global Commercial Operations', 'pay': '2.97M', 'exercised': 'N/A', 'age': '63'}"
AMPH,"Amphastar Pharmaceuticals, Inc.",http://www.amphastar.com,Healthcare,Drug Manufacturers - Other,"1,541","Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The companys product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; and procainamide for documented ventricular arrhythmias. In addition, the company manufactures and distributes recombinant human insulin and porcine insulin. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate that is intended to be used for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was established in 1996 and is headquartered in Rancho Cucamonga, California.","{'name': 'Dr. Ziping  Luo Ph.D.', 'title': 'Chairman of The Board, Chief Scientist and Chief Operating Officer', 'pay': '1.21M', 'exercised': 'N/A', 'age': '68'}","{'name': 'Dr. Yongfeng  Zhang Ph.D.', 'title': 'Chief Exec. Officer, Chief Science Officer and Director', 'pay': '1.55M', 'exercised': 'N/A', 'age': '71'}","{'name': 'Mr. Jason B. Shandell J.D., M.B.A.', 'title': 'Pres, Gen. Counsel & Director', 'pay': '961.67k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Mr. William J. Peters', 'title': 'CFO, Sr. VP & Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}","{'name': 'Ms. Diane G. Gerst B.A.', 'title': 'EVP of Quality Assurance & Regulatory Affairs', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}"
AMRN,Amarin Corporation plc,http://www.amarincorp.com,N/A,N/A,N/A,"Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companys lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its product principally to wholesalers and specialty pharmacy providers. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.","{'name': 'Mr. John F. Thero', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.11M', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Michael W. Kalb CPA', 'title': 'Chief Financial Officer and Sr. VP', 'pay': '293.2k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Steven B. Ketchum', 'title': 'Chief Scientific Officer, Pres of R&D and Sr. VP', 'pay': '631.56k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Joseph T. Kennedy J.D.', 'title': 'Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec.', 'pay': '672.54k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Frederick W. Ahlholm CPA', 'title': 'Chief Accounting Officer and VP of Fin. & Admin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}"
ANAB,"AnaptysBio, Inc.",http://www.anaptysbio.com,N/A,N/A,N/A,"AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The companys proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.","{'name': 'Mr. Hamza  Suria M.Sc., M.B.A.', 'title': 'Pres, CEO & Director', 'pay': '578.6k', 'exercised': 'N/A', 'age': '42'}","{'name': 'Prof. Marco  Londei M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '484.28k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. Andrea B. Cubitt Ph.D.', 'title': 'Co-Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Dominic G. Piscitelli M.B.A., CPA', 'title': 'CFO & Principal Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '43'}","{'name': 'Mr. Bob  Daniel', 'title': 'Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ANIP,"ANI Pharmaceuticals, Inc.",http://www.anipharmaceuticals.com,Healthcare,Biotechnology,143,"ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.","{'name': 'Mr. Arthur S. Przybyl', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1M', 'exercised': '3.43M', 'age': '61'}","{'name': 'Mr. Stephen P. Carey', 'title': 'Chief Financial Officer and VP of Fin.', 'pay': '325.86k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. James G. Marken', 'title': 'Sr. VP of Operations & Product Devel.', 'pay': '491.05k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Robert W. Schrepfer', 'title': 'Sr. VP of Bus. Devel. & Specialty Sales', 'pay': '475.73k', 'exercised': '142.14k', 'age': '46'}","{'name': 'Dr. David J. Sullivan Ph.D.', 'title': 'VP of Quality Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ARDX,"Ardelyx, Inc.",http://www.ardelyx.com,N/A,N/A,N/A,"Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.","{'name': 'Mr. Michael G. Raab', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '777.4k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Reginald  Seeto M.D., MBBS', 'title': 'Chief Operating Officer and Exec. VP', 'pay': '375.3k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Mark E. Kaufmann MBA', 'title': 'CFO & Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Bryan  Shaw', 'title': 'Chief Accounting Officer, VP and Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}","{'name': 'Mr. Jeffrey W. Jacobs Ph.D.', 'title': 'Sr. VP of Technical Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}"
ARNA,"Arena Pharmaceuticals, Inc.",http://www.arenapharm.com,Healthcare,Biotechnology,106,"Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The companys proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.","{'name': 'Mr. Amit D. Munshi', 'title': 'Pres, CEO & Director', 'pay': '644.43k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Kevin R. Lind', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '342.33k', 'exercised': 'N/A', 'age': '41'}","{'name': 'Mr. Steven W. Spector J.D.', 'title': 'Exec. VP, Gen. Counsel and Sec.', 'pay': '638.3k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Vincent E.  Aurentz', 'title': 'Chief Bus. Officer and Exec. VP', 'pay': '274.24k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Ms. Cate  Scanlon', 'title': 'VP of Global HR', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ARRY,Array BioPharma Inc.,http://www.arraybiopharma.com,Healthcare,Biotechnology,209,"Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companys drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.","{'name': 'Mr. Ron  Squarer BSc (Biochemistry), MBA', 'title': 'CEO & Director', 'pay': '1.06M', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Jason  Haddock', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Andrew R. Robbins', 'title': 'Chief Operating Officer', 'pay': '684.38k', 'exercised': 'N/A', 'age': '42'}","{'name': 'Dr. Victor  Sandor M.D., C.M', 'title': 'Chief Medical Officer', 'pay': '745.35k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Nicholas A. Saccomano Ph.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '59'}"
ARWR,"Arrowhead Pharmaceuticals, Inc.",http://www.arrowheadpharma.com,N/A,N/A,N/A,"Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.","{'name': 'Dr. Christopher R. Anzalone Ph.D.', 'title': 'CEO, Pres & Director', 'pay': '1.06M', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Kenneth A. Myszkowski MBA, CPA', 'title': 'Chief Financial Officer', 'pay': '476.13k', 'exercised': '119.8k', 'age': '51'}","{'name': 'Dr. Bruce D. Given M.D.', 'title': 'Chief Operating Officer', 'pay': '694.03k', 'exercised': 'N/A', 'age': '63'}","{'name': ""Mr. Patrick  O'Brien J.D., PharmD"", 'title': 'Gen. Counsel', 'pay': '571.93k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Mark M. Davis Ph.D.', 'title': 'Founder and Founder & Director of Insert Therapeutics Inc & Calando', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ASND,Ascendis Pharma A/S,http://www.ascendispharma.com,Healthcare,Biotechnology,101,"Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.","{'name': 'Mr. Michael Wolff Jensen L.L.M.', 'title': 'Chairman, Sr. VP, Gen. Counsel and Member of Exec. Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. Jan M??ller Mikkelsen', 'title': 'Chief Exec. Officer, Pres, Member of Exec. Board and Exec. Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Scott T. Smith', 'title': 'Chief Financial Officer and Sr. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}","{'name': 'Mrs. Lotte  S??nderbjerg', 'title': 'Chief Admin. Officer, Sr. VP and Member of Exec. Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Grethe  Rasmussen Ph.D.', 'title': 'Sr. VP of Product Devel. and Member of Exec. Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}"
ATNX,"Athenex, Inc.",http://www.athenex.com,N/A,N/A,N/A,"Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. The company also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is based in Buffalo, New York.","{'name': 'Dr. Yiu-Nam  Lau', 'title': 'Chairman & Chief Exec. Officer', 'pay': '521.69k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Jeffrey M. Yordon', 'title': 'COO & Pres of Pharmaceutical Division', 'pay': '256.77k', 'exercised': 'N/A', 'age': '69'}","{'name': 'Dr. Simon C. Pedder Ph.D.', 'title': 'Chief Bus. and Strategy Officer of Proprietary Products', 'pay': '188.95k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Allen  Barnett Ph.D.', 'title': 'Co-Founder and Pres Emeritus', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. J. Nick Riehle MBA', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '65'}"
ATRA,"Atara Biotherapeutics, Inc.",http://www.atarabio.com,N/A,N/A,N/A,"Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. Its clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. The company is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cells ability to target specific viral proteins implicated in disease. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company also has a clinical trial collaboration agreement with Merck Sharp & Dohme B.V. to evaluate ATA129 in combination with Merck anti-programmed death receptor-1 therapy and Keytruda in patients with platinum resistant or recurrent epstein-barr virus-associated nasopharyngeal carcinoma. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.","{'name': 'Dr. Isaac E. Ciechanover M.D.', 'title': 'CEO, Pres & Director', 'pay': '879.73k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. Christopher M. Haqq M.D., Ph.D.', 'title': 'Exec. VP of R&D and Chief Scientific Officer', 'pay': '574.52k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Gad  Soffer', 'title': 'Exec. VP & Chief Strategy Officer', 'pay': '492.15k', 'exercised': 'N/A', 'age': '41'}","{'name': 'Mr. John F. McGrath Jr.', 'title': 'Exec. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Joseph  Newell', 'title': 'Exec. VP & Chief Technical Operations Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '48'}"
AUPH,Aurinia Pharmaceuticals Inc.,http://www.auriniapharma.com,N/A,N/A,N/A,"Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.","{'name': 'Dr. Richard M. Glickman L.L.D. (Hon)', 'title': 'Founder, Chairman & CEO', 'pay': '88.42k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Michael R. Martin', 'title': 'Co-Founder and Chief Operating Officer', 'pay': '280.66k', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Dennis  Bourgeault C.A.', 'title': 'Chief Financial Officer and Sec.', 'pay': '261.3k', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)', 'title': 'Exec. VP of Corp. Devel.', 'pay': '257.46k', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Neil  Solomons M.D.', 'title': 'Chief Medical Officer', 'pay': '334.8k', 'exercised': 'N/A', 'age': 'N/A'}"
AVDL,Avadel Pharmaceuticals plc,http://www.avadel.com,N/A,N/A,N/A,"Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The companys owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection. The company also provides Karbinal ER, an H1 receptor antagonist used to treat children with seasonal and perennial allergic rhinitis; AcipHex Sprinkle for the treatment of gastroesophageal reflux disease; Flexichamber, a collapsible holding chamber that administers aerosolized medication from pressurized metered dose inhalers; and Cefaclor for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections. In addition, its product candidates comprise sodium oxybate for narcolepsy; Hydromorphone/Trigger Lock for pain; Exenatide, a Medusa-based injectable formulation for diabetes; and LiquiTime for cough/cold. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.","{'name': 'Mr. Michael S. Anderson', 'title': 'CEO & Director', 'pay': '914.47k', 'exercised': 'N/A', 'age': '69'}","{'name': 'Mr. Michael F. Kanan', 'title': 'CFO & Sr. VP', 'pay': '474.35k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Phillandas T. Thompson J.D., M.B.A.', 'title': 'Sr. VP, Gen. Counsel & Corp. Sec.', 'pay': '432.5k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Ms. Sandra L. Hatten', 'title': 'Sr. VP of Quality & Regulatory Affairs', 'pay': '424.6k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. David  Monteith Ph.D.', 'title': 'VP of R&D', 'pay': '404.32k', 'exercised': 'N/A', 'age': '54'}"
AVXS,"AveXis, Inc.",http://www.avexis.com,N/A,N/A,N/A,"AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.","{'name': 'Mr. Sean P. Nolan', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '628.46k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Sukumar  Nagendran M.D.', 'title': 'Chief Medical Officer and Sr. VP', 'pay': '595k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Phillip B. Donenberg CPA', 'title': 'Sr. VP, CFO & Principal Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Brian  K. Kaspar Ph.D.', 'title': 'Chief Scientific Officer, Director and Member of Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}","{'name': 'Mr. Michael B. Johannesen', 'title': 'Chief Compliance Officer, Sr. VP and Gen. Counsel', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}"
AXON,Axovant Sciences Ltd.,http://www.axovant.com,Healthcare,Biotechnology,89,"Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimers disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.","{'name': 'Dr. Gregory M. Weinhoff M.D., MBA', 'title': 'Principal Financial Officer', 'pay': '561.03k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. David T. Hung M.D.', 'title': 'Principal Exec. Officer & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '60'}","{'name': 'Ms. Marion E. McCourt', 'title': 'Pres & Principal Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Michael  Adasczik', 'title': 'Principal Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}","{'name': 'Mr. Jonathan  Neely', 'title': 'Head of Investor Relations & Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
BCRX,"BioCryst Pharmaceuticals, Inc.",http://www.biocryst.com,N/A,N/A,N/A,"BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","{'name': 'Mr. Jon P. Stonehouse', 'title': 'Chief Exec. Officer, Pres and Exec. Director', 'pay': '533.98k', 'exercised': '81.93k', 'age': '57'}","{'name': 'Mr. Thomas R. Staab II, CPA', 'title': 'Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer', 'pay': '436.67k', 'exercised': '89.58k', 'age': '50'}","{'name': 'Dr. William P. Sheridan MBBS', 'title': 'Chief Medical Officer and Sr. VP', 'pay': '494.11k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Dr. Yarlagadda S. Babu Ph.D.', 'title': 'Sr. VP of Drug Discovery', 'pay': '386.4k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Ms. Lynne M. Powell', 'title': 'Chief Commercial Officer and Sr. VP', 'pay': '390.14k', 'exercised': 'N/A', 'age': '51'}"
BGNE,"BeiGene, Ltd.",http://www.beigene.com,N/A,N/A,N/A,"BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The companys clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has a strategic collaboration with Celgene Corporation to develop and commercialize BeiGene, Ltd.s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317. BeiGene, Ltd. was founded in 2010 and is based in Camana Bay, Cayman Islands.","{'name': 'Mr. John V. Oyler', 'title': 'Founder, Chairman and Chief Exec. Officer', 'pay': '677.96k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Xiaodong  Wang Ph.D.', 'title': 'Co-Founder, Chairman of the Scientific Advisory Board and Director', 'pay': '3.31M', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Heng  Liang Ph.D.', 'title': 'Chief Financial Officer and Chief Strategy Officer', 'pay': '539.88k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Ji  Li Ph.D.', 'title': 'Exec. VP & Global Head of Bus. Devel.', 'pay': '323.21k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Ms. Maggie  Liu', 'title': 'Head of Operations and VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
BIIB,Biogen Inc.,http://www.biogen.com,Healthcare,Biotechnology,"7,400","Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The companys Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkins lymphoma; and Aducanumab and E2609 for Alzheimers disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The companys Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Michel  Vounatsos', 'title': 'CEO & Director', 'pay': '2.65M', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Michael D. Ehlers M.D., Ph.D.', 'title': 'Exec. VP and Head of R&D', 'pay': '2.1M', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Jeffrey D. Capello', 'title': 'Exec. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Gregory F. Covino', 'title': 'Chief Accounting Officer & VP of Fin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Mark J. Hernon', 'title': 'Sr. VP & Chief Information Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '54'}"
BIVV,Bioverativ Inc.,http://www.bioverativ.com,,,350,"Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States and Japan. The company offers ELOCTATE, an antihemophilic factor (recombinant) Fc fusion protein; and ALPROLIX, a coagulation factor IX (Recombinant) Fc fusion protein for the treatment of hemophilia A and B. It is also developing BIVV 001 (rFVIIIFc-VWF-XTEN), a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV 002 (rFIXFc-XTEN), a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A. The company has collaboration with Swedish Orphan Biovitrum AB (publ) to develop and commercialize ELOCTATE and ALPROLIX worldwide; and a research collaboration with Bicycle Therapeutics Ltd. for the discovery, development, and commercialization of therapies for haemophilia and sickle cell diseases. Bioverativ Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.","{'name': 'Mr. John G. Cox M.B.A.', 'title': 'Chief Exec. Officer and Director', 'pay': '1.73M', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. John T. Greene', 'title': 'Chief Financial Officer, Exec. VP and Treasurer', 'pay': '587.24k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Rogerio Coelho Vivaldi M.D., MBA', 'title': 'Chief Global Therapeutic Operations Officer and Exec. VP', 'pay': '658.89k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Ms. Diantha  Duvall', 'title': 'Chief Accounting Officer and VP of Fin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '46'}","{'name': 'Susan  Altschuller Ph.D.', 'title': 'Exec. Director of Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
BLCM,"Bellicum Pharmaceuticals, Inc.",http://www.bellicum.com,N/A,N/A,N/A,"Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The companys preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.","{'name': 'Mr. Alan A. Musso CPA, C.M.A.', 'title': 'Chief Financial Officer and Treasurer', 'pay': '488.97k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Thomas J. Farrell', 'title': 'Consultant', 'pay': '681.19k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Annemarie  Moseley M.D., Ph.D.', 'title': 'Consultant', 'pay': '550.01k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Richard A. Fair', 'title': 'CEO, Pres & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. David M. Spencer Ph.D.', 'title': 'Co-Founder and Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}"
BLKFDS,N/A,N/A,N/A,N/A,N/A,N/A,,,,,
BLUE,"bluebird bio, Inc.",http://www.bluebirdbio.com,Healthcare,Biotechnology,418,"bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease. The companys lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Nick  Leschly', 'title': 'Pres, CEO & Director', 'pay': '814.62k', 'exercised': '732.07k', 'age': '45'}","{'name': 'Mr. Jeffrey T. Walsh MBA', 'title': 'Chief Financial & Strategy Officer & Principal Accounting Officer', 'pay': '568.05k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Ms. Susanna Gatti High', 'title': 'Chief Operating Officer', 'pay': '16.63k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Philip D. Gregory D. Phil.', 'title': 'Chief Scientific Officer', 'pay': '622.15k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. David M. Davidson M.D.', 'title': 'Chief Medical Officer', 'pay': '554.35k', 'exercised': '299.61k', 'age': '54'}"
BMRN,BioMarin Pharmaceutical Inc.,http://www.biomarin.com,Healthcare,Biotechnology,"2,293","BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.","{'name': 'Mr. Jean-Jacques  Bienaim?? MBA', 'title': 'Chairman & Chief Exec. Officer', 'pay': '2.47M', 'exercised': '65.74M', 'age': '65'}","{'name': 'Mr. Daniel K. Spiegelman B.A., M.B.A.', 'title': 'Exec. VP & CFO', 'pay': '934.12k', 'exercised': '860.68k', 'age': '59'}","{'name': 'Dr. Robert A. Baffi Ph.D., MBA', 'title': 'Exec. VP of Technical Operations', 'pay': '873.36k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Jeffrey Robert Ajer', 'title': 'Exec. VP & Chief Commercial Officer', 'pay': '864.5k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Henry J. Fuchs M.D., Ph.D.', 'title': 'Pres of Worldwide R&D', 'pay': '1.08M', 'exercised': '2.86M', 'age': '60'}"
BOLD,"Audentes Therapeutics, Inc.",http://www.audentestx.com,N/A,N/A,N/A,"Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.","{'name': 'Mr. Matthew R. Patterson', 'title': 'Chief Exec. Officer, Pres & Director', 'pay': '648.76k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Thomas P. Soloway', 'title': 'CFO and Sr. VP', 'pay': '468.65k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Ms. Natalie C. Holles', 'title': 'Chief Operating Officer and Sr. VP', 'pay': '463.24k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Dr. John T. Gray Ph.D.', 'title': 'Chief Scientific Officer and Sr. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Ms. Dawn  Blessing', 'title': 'VP of Corp. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
BPMC,Blueprint Medicines Corporation,http://www.blueprintmedicines.com,N/A,N/A,N/A,"Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Daniel S. Lynch M.B.A.', 'title': 'Exec. Chairman', 'pay': '68.58k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Jeffrey W. Albers J.D., MBA', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '758.95k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. Alexis  Borisy A.M.', 'title': 'Co-Founder and Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Marion  Dorsch Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '190.96k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Ms. Tracey L. Mccain Esq.', 'title': 'Chief Legal Officer and Exec. VP', 'pay': '280.96k', 'exercised': 'N/A', 'age': '50'}"
CALA,"Calithera Biosciences, Inc.",http://www.calithera.com,N/A,N/A,N/A,"Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize Symbiosciences portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.","{'name': 'Dr. Susan M. Molineaux Ph.D.', 'title': 'Co-Founder, CEO, Pres & Director', 'pay': '716.96k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Dr. Keith  Orford M.D., Ph.D.', 'title': 'Sr. VP of Clinical Devel.', 'pay': '564.29k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Ms. Jennifer  McNealey', 'title': 'VP of Investor Relations & Strategy', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Sumita  Ray', 'title': 'Sr. VP, Gen. Counsel & Chief Compliance Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Curtis C. Hecht', 'title': 'Sr. VP of Bus. & Corp. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '47'}"
CARA,"Cara Therapeutics, Inc.",http://www.caratherapeutics.com,N/A,N/A,N/A,"Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companys lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.","{'name': 'Dr. Derek T. Chalmers Ph.D., D.Sc.', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Director', 'pay': '723.35k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Fr??d??rique  Menzaghi Ph.D.', 'title': 'Sr. VP of R&D', 'pay': '533.63k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Joseph  Stauffer D.O., M.B.A.', 'title': 'Chief Medical Officer', 'pay': '645.76k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Michael E. Lewis Ph.D.', 'title': 'Co-Founder and Chief Scientific Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': '66'}","{'name': 'Dr. Mani  Mohindru Ph.D.', 'title': 'CFO & Chief Strategy Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '46'}"
CASC,"Cascadian Therapeutics, Inc.",http://www.cascadianrx.com,N/A,N/A,N/A,"Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington.","{'name': 'Mr. Scott D. Myers', 'title': 'Pres, CEO & Director', 'pay': '744.57k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Ms. Julia M. Eastland M.B.A.', 'title': 'CFO, Chief Bus. Officer & Sec.', 'pay': '467.44k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Gary W. Christianson PE', 'title': 'Chief Operating Officer', 'pay': '443.02k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Dr. Scott Robert Peterson Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '494.44k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Gwen A. Fyfe M.D.', 'title': 'Consultant & Director', 'pay': '48.9k', 'exercised': 'N/A', 'age': '65'}"
CBPO,"China Biologic Products Holdings, Inc.",http://www.chinabiologic.com,N/A,N/A,N/A,"China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the Peoples Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (pH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; human cytomegalovirus immunoglobulin; human coagulation factor IX; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the Peoples Republic of China.","{'name': 'Mr. Xiaoying  Gao', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '1.4M', 'exercised': '7.55M', 'age': '67'}","{'name': 'Mr. Ming  Yang', 'title': 'Chief Financial Officer', 'pay': '678.5k', 'exercised': '2.9M', 'age': '46'}","{'name': 'Mr. Ming  Yin', 'title': 'Sr. Corp. VP', 'pay': '491.68k', 'exercised': '3.93M', 'age': '40'}","{'name': 'Ms. Zhijing  Liu', 'title': 'Corp. VP', 'pay': '233.34k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Mr. Gang  Yang', 'title': 'Corp. VP and Gen. Mang. of Guizhou Taibang', 'pay': '344.25k', 'exercised': '5.31M', 'age': '53'}"
CCXI,"ChemoCentryx, Inc.",http://www.chemocentryx.com,Healthcare,Biotechnology,62,"ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohns diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.","{'name': 'Dr. Thomas J. Schall Ph.D.', 'title': 'Founder, Chairman, Chief Exec. Officer and Pres', 'pay': '858.64k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Ms. Susan M. Kanaya', 'title': 'Chief Financial & Admin. Officer, Exec. VP and Sec.', 'pay': '597.52k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Markus J. Cappel Ph.D.', 'title': 'Chief Bus. Officer and Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Rajinder  Singh Ph.D.', 'title': 'Sr. VP of Research', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Jan L. Hillson M.D.', 'title': 'Sr. VP of Drug Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '65'}"
CELG,Celgene Corporation,http://www.celgene.com,Healthcare,Biotechnology,"7,132","Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companys products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.","{'name': 'Mr. Robert J. Hugin MBA', 'title': 'Exec. Chairman', 'pay': '8.04M', 'exercised': '1.74M', 'age': '63'}","{'name': 'Mr. Mark J. Alles', 'title': 'CEO & Director', 'pay': '4.77M', 'exercised': '1.6M', 'age': '59'}","{'name': 'Mr. Scott Andrew Smith', 'title': 'Pres & COO', 'pay': '2.01M', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Peter N. Kellogg BSE, MBA', 'title': 'Exec. VP, CFO & Chief Accounting Officer', 'pay': '3.58M', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Rupert J. Vessey MA, BM BCh, FRCP, DPhil', 'title': 'Exec. VP and Pres of Research & Early Devel.', 'pay': '1.76M', 'exercised': 'N/A', 'age': '53'}"
CERS,Cerus Corporation,http://www.cerus.com,Healthcare,Biotechnology,204,"Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The companys INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.","{'name': 'Mr. William M. Greenman', 'title': 'Pres, Chief Exec. Officer & Director', 'pay': '884.97k', 'exercised': '31.35k', 'age': '50'}","{'name': 'Dr. Laurence M. Corash M.D.', 'title': 'Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director', 'pay': '595.71k', 'exercised': '36.39k', 'age': '73'}","{'name': 'Mr. Kevin D. Green', 'title': 'VP - Fin. & CFO', 'pay': '476.93k', 'exercised': '15.48k', 'age': '45'}","{'name': 'Dr. Richard J. Benjamin MBChB, Ph.D.', 'title': 'Chief Medical Officer', 'pay': '523.13k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Vivek K. Jayaraman', 'title': 'Chief Commercial Officer', 'pay': '191.06k', 'exercised': 'N/A', 'age': '42'}"
CHRS,"Coherus Biosciences, Inc.",http://www.coherus.com,N/A,N/A,N/A,"Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companys product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohns Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.","{'name': 'Mr. Dennis M. Lanfear', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '1.12M', 'exercised': 'N/A', 'age': '63'}","{'name': 'Dr. Jean-Fr??d??ric  Viret Ph.D.', 'title': 'Chief Financial Officer', 'pay': '547.92k', 'exercised': '263.14k', 'age': '52'}","{'name': 'Dr. Peter K. Watler Ph.D.', 'title': 'Chief Technical Officer', 'pay': '512.41k', 'exercised': '2.36M', 'age': '56'}","{'name': 'Dr. Alan C. Herman Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '408.95k', 'exercised': 'N/A', 'age': '70'}","{'name': 'Dr. Barbara K. Finck M.D.', 'title': 'Chief Medical Officer', 'pay': '604.04k', 'exercised': 'N/A', 'age': '71'}"
CLDX,"Celldex Therapeutics, Inc.",http://www.celldextherapeutics.com,N/A,N/A,N/A,"Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.","{'name': 'Mr. Anthony S. Marucci M.B.A.', 'title': 'Co-Founder, Pres, CEO & Director', 'pay': '873.75k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Tibor  Keler Ph.D.', 'title': 'Founder, Chief Scientific Officer and Exec. VP', 'pay': '552.71k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Ms. Elizabeth  Crowley', 'title': 'Chief Product Devel. Officer and Sr. VP', 'pay': '423.2k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Sam  Martin', 'title': 'CFO & Sr. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Sarah  Cavanaugh', 'title': 'Sr. VP of Corp. Affairs & Admin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
CLLS,Cellectis S.A.,http://www.cellectis.com,,,114,"Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companys products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.","{'name': 'Dr. Andr??  Choulika Ph.D.', 'title': 'Co-Founder, Chairman and Chief Exec. Officer', 'pay': '408.76k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. David J. D. Sourdive Ph.D.', 'title': 'Co-Founder, Exec. VP - Technical Operations and Director', 'pay': '312.54k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Eric  Dutang', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}","{'name': 'Dr. Mathieu  Simon M.D.', 'title': 'Exec. VP, COO, Interim Chief Medical Officer & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. Philippe  Duchateau Ph.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}"
CLVS,"Clovis Oncology, Inc.",http://www.clovisoncology.com,N/A,N/A,N/A,"Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.","{'name': 'Mr. Patrick J. Mahaffy MA', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Exec. Director', 'pay': '788.62k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Gillian C. Ivers-Read BSc', 'title': 'Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations', 'pay': '735.17k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Mr. Daniel W. Muehl CPA', 'title': 'Sr. VP of Fin. and Principal Financial & Accounting Officer', 'pay': '492.36k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Lindsey  Rolfe BSc, MB ChB, MRCP, FFPM', 'title': 'Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance', 'pay': '724.92k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Corwin  Dale Hooks', 'title': 'Chief Commercial Officer and Sr. VP', 'pay': '585.27k', 'exercised': 'N/A', 'age': '51'}"
CLXT,"Calyxt, Inc.",http://www.calyxt.com,N/A,N/A,N/A,"Calyxt, Inc., an agriculture biotechnology company, develops healthier specialty food ingredients and agricultural food crops using gene editing technology for plants. It engages in the development of high oleic soybeans, powdery mildew resistant wheat, cold storable potatoes, high fiber wheat, reduced browning potatoes, and herbicide tolerant wheat. The Company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. The company was founded in 2010 and is headquartered in New Brighton, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.","{'name': 'Mr. Federico A.  Tripodi', 'title': 'Chief Exec. Officer', 'pay': '384.76k', 'exercised': 'N/A', 'age': '41'}","{'name': 'Dr. Daniel  Voytas Ph.D.', 'title': 'Founder & Chief Science Officer', 'pay': '280.24k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Bryan W. J. Corkal', 'title': 'CFO and Principal Financial & Accounting Officer', 'pay': '19.32k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Simon  Harnest', 'title': 'VP of Fin. & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Joseph B. Saluri J.D.', 'title': 'Gen. Counsel & Exec. VP of Corp. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}"
CMRX,"Chimerix, Inc.",http://www.chimerix.com,N/A,N/A,N/A,"Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companys lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.","{'name': 'Dr. M. Michelle Berrey M.D., MPH.', 'title': 'Pres, CEO & Director', 'pay': '724.37k', 'exercised': '9.58k', 'age': '50'}","{'name': 'Mr. Timothy W. Trost CPA', 'title': 'Sr. VP, CFO & Corp. Sec.', 'pay': '460.78k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Ms. Linda M. Richardson', 'title': 'Chief Strategy & Commercial Officer', 'pay': '471.32k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. William Garrett Nichols M.D., MS', 'title': 'Chief Medical Officer', 'pay': '528.01k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Dr. Roy W. Ware Ph.D., MBA', 'title': 'Chief Manufacturing & Technology Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
CNCE,"Concert Pharmaceuticals, Inc.",http://www.concertpharma.com,N/A,N/A,N/A,"Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The companys clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimers disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.","{'name': 'Dr. Roger D. Tung Ph.D.', 'title': 'Co-Founder, CEO, Pres & Director', 'pay': '709.62k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Ms. Nancy  Stuart', 'title': 'Chief Operating Officer', 'pay': '517.67k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. James V. Cassella Ph.D.', 'title': 'Chief Devel. Officer & Sr. VP', 'pay': '529.09k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Ryan  Lynch', 'title': 'Principal Financial Officer, Principal Accounting Officer & Corp. Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Justine E. Koenigsberg', 'title': 'VP of Corp. Communications & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
COLL,"Collegium Pharmaceutical, Inc.",http://www.collegiumpharma.com,N/A,N/A,N/A,"Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. The company also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.","{'name': 'Mr. Michael T. Heffernan B.S. Pharm, R.Ph.', 'title': 'Founder, Chairman, Chief Exec. Officer, Pres, Treasurer and Sec.', 'pay': '736k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Paul  Brannelly', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '452.07k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Joseph J. Ciaffoni', 'title': 'Chief Operating Officer & Exec. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Alison B. Fleming Ph.D.', 'title': 'Chief Technology Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '43'}","{'name': 'Mr. Jack  Maroney', 'title': 'VP of Sales', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
CORI,"Corium International, Inc.",http://www.coriumgroup.com,Healthcare,Biotechnology,213,"Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The companys products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trial for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trial for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Ropinirole TDS that is in preclinical stage for the treatment of Parkinson's disease; MicroCor Zolmitriptan that is in preclinical stage for treatment of migraine; and generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements primarily with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Endo Pharmaceuticals, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.","{'name': 'Mr. Peter D. Staple', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '465.65k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Mr. Robert S. Breuil', 'title': 'Chief Financial Officer', 'pay': '366.53k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Joseph J. Sarret M.D., J.D.', 'title': 'Chief Bus. Officer', 'pay': '337.94k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Timothy  Sweemer CPA', 'title': 'Chief Accounting Officer, VP of Admin. and Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Parminder  Singh Ph.D.', 'title': 'Chief Technology Officer and VP of R&D', 'pay': 'N/A', 'exercised': 'N/A', 'age': '54'}"
CRBP,"Corbus Pharmaceuticals Holdings, Inc.",http://www.corbuspharma.com,Healthcare,Biotechnology,25,"Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.","{'name': 'Dr. Yuval  Cohen Ph.D.', 'title': 'CEO & Director', 'pay': '555k', 'exercised': 'N/A', 'age': '43'}","{'name': 'Dr. Mark A. Tepper Ph.D.', 'title': 'Co-Founder, Pres & Chief Scientific Officer', 'pay': '464k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. Barbara  White M.D.', 'title': 'Chief Medical Officer', 'pay': '483k', 'exercised': 'N/A', 'age': '68'}","{'name': 'Mr. Sean F. Moran CPA, MBA', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '60'}","{'name': 'Scott  Constantine M.S.', 'title': 'Director of Clinical Research & Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
CRIS,"Curis, Inc.",http://www.curis.com,Healthcare,Biotechnology,58,"Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.","{'name': 'Dr. Ali  Fattaey Ph.D.', 'title': 'Pres, CEO & Director', 'pay': '716.43k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. James E. Dentzer', 'title': 'CFO & Chief Admin. Officer', 'pay': '470.35k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. David  Tuck M.D.', 'title': 'Sr. VP & Chief Medical Officer', 'pay': '466.28k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. Daniel R. Passeri MSc., J.D.', 'title': 'Consultant', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Mark W. Noel', 'title': 'VP of Technology Management & Intellectual Property', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}"
CRSP,CRISPR Therapeutics AG,http://crisprtx.com,,,93,"CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.","{'name': 'Dr. Rodger  Novak M.D.', 'title': 'Co-Founder, Pres & Director', 'pay': '711.76k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Kala  Subramanian Ph.D.', 'title': 'Chief of Staff and Sr. VP of Strategic Devel. & Operations', 'pay': '399.67k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Samarth  Kulkarni Ph.D.', 'title': 'Chief Exec. Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '39'}","{'name': 'Dr. Chad  Cowan', 'title': 'Scientific Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Michael John Tomsicek M.B.A', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}"
CRVS,"Corvus Pharmaceuticals, Inc.",http://www.corvuspharma.com,N/A,N/A,N/A,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.","{'name': 'Dr. Richard A. Miller M.D.', 'title': 'Co-Founder, Chairman, Chief Exec. Officer and Pres', 'pay': '291.77k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Dr. Peter A. Thompson M.D., FACP', 'title': 'Co-Founder and Director', 'pay': '36.41k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Leiv  Lea', 'title': 'CFO & Chief Bus. Officer', 'pay': '264.9k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Dr. Joseph J. Buggy Ph.D.', 'title': 'Co-Founder and Strategic Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Daniel W. Hunt', 'title': 'Sr. VP & Chief Bus. Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
CTMX,"CytomX Therapeutics, Inc.",http://www.cytomx.com,N/A,N/A,N/A,"CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. Its other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188. In addition, the company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., M D Anderson Cancer Center, Pfizer Inc., and The University of Texas to develop Probody therapeutics. It also has a strategic collaboration with Amgen Inc. to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor, a validated oncology target expressed on multiple human cancer types. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.","{'name': 'Dr. Sean A. McCarthy D.Phil.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '749.03k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Frederick W. Gluck', 'title': 'Co-Founder and Director', 'pay': '47.5k', 'exercised': 'N/A', 'age': '83'}","{'name': 'Dr. W. Michael Kavanaugh M.D.', 'title': 'Chief Scientific Officer and Head of Research & Non-Clinical Devel.', 'pay': '595.29k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Dr. Rachel Wallach Humphrey M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '622.62k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Prof. Patrick S. Daugherty Ph.D.', 'title': 'Founder and Member of Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
CYTK,"Cytokinetics, Incorporated",http://www.cytokinetics.com,Healthcare,Biotechnology,127,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.","{'name': 'Mr. Robert I. Blum', 'title': 'Pres, CEO & Director', 'pay': '941.67k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Andrew A. Wolff M.D., F.A.C.C.', 'title': 'Sr. VP & Chief Medical Officer', 'pay': '494.47k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Dr. Fady Ibraham Malik M.D., Ph.D., FACC', 'title': 'Exec. VP of R&D', 'pay': '626.7k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Bradley Paul Morgan Ph.D.', 'title': 'Sr. VP of Research & Non-Clinical Devel.', 'pay': '449.03k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. James A. Spudich Ph.D.', 'title': 'Co-Founder & Member of Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '75'}"
DBVT,DBV Technologies S.A.,http://www.dbv-technologies.com,,,192,"DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cows milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hens egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohns disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.","{'name': 'Dr. Pierre-Henri  Benhamou M.D.', 'title': 'Co-Founder, Chairman and Chief Exec. Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. David  Schilansky', 'title': 'Chief Financial Officer and Chief Operating Officer', 'pay': '580.38k', 'exercised': 'N/A', 'age': '42'}","{'name': 'Mr. Daniel B. Soland', 'title': 'Consultant and Independent Director', 'pay': '47.6k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Jorge  Ronco Ph.D., MBA', 'title': 'Co-Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Bertrand  Dupont', 'title': 'Co-Founder and Chief Technical Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '65'}"
DEPO,"Depomed, Inc.",http://www.depomed.com,N/A,N/A,N/A,"Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. The company sells its products to wholesalers and retail pharmacies. It also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.","{'name': 'Mr. August J. Moretti J.D., Esq.', 'title': 'CFO & Sr. VP', 'pay': '611.34k', 'exercised': '71.74k', 'age': '66'}","{'name': 'Mr. Matthew M. Gosling', 'title': 'Sr. VP, Gen. Counsel & Sec.', 'pay': '712.74k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Arthur Joseph Higgins', 'title': 'CEO, Pres & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Sean P. McKercher', 'title': 'Sr. VP of Marketing & Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Santosh J. Vetticaden M.D., Ph.D.', 'title': 'Sr. VP and Chief Medical & Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}"
DERM,"Dermira, Inc.",http://www.dermira.com,N/A,N/A,N/A,"Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The companys late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.","{'name': 'Mr. Thomas G. Wiggans', 'title': 'Co-Founder, Chairman and Chief Exec. Officer', 'pay': '812.5k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Dr. Eugene Andrew Bauer M.D.', 'title': 'Co-Founder, Chief Medical Officer and Director', 'pay': '518.58k', 'exercised': 'N/A', 'age': '76'}","{'name': 'Mr. Christopher M. Griffith', 'title': 'Co-Founder and Sr. VP of Corp. Devel. & Strategy', 'pay': '391.74k', 'exercised': '277.33k', 'age': '42'}","{'name': 'Mr. Andrew L. Guggenhime', 'title': 'Chief Financial Officer and Chief Operating Officer', 'pay': '551.14k', 'exercised': '1.65M', 'age': '50'}","{'name': 'Mr. Luis C. Pe??a', 'title': 'Chief Devel. Officer', 'pay': '515.64k', 'exercised': '569.53k', 'age': '55'}"
DOVA,"Dova Pharmaceuticals, Inc.",http://www.dova.com,N/A,N/A,N/A,"Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.","{'name': 'Mr. Alexander C. Sapir', 'title': 'CEO, Pres & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Douglas  Blankenship', 'title': 'CFO & Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Lee F. Allen M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '66'}","{'name': 'Mr. Kevin  Laliberte', 'title': 'Sr. VP of Product Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '40'}",
ECYT,"Endocyte, Inc.",http://www.endocyte.com,N/A,N/A,N/A,"Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The companys products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.","{'name': 'Mr. Michael A. Sherman', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '545.98k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Philip S. Low Ph.D.', 'title': 'Co-Founder, Chief Science Officer and Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '70'}","{'name': 'Ms. Katherine K. Parker', 'title': 'VP of HR', 'pay': '347.24k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Alison A. Armour M.B.,Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR', 'title': 'Chief Medical Officer', 'pay': '460.7k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Christopher P. Leamon Ph.D.', 'title': 'VP of R&D', 'pay': '449.04k', 'exercised': '28.97k', 'age': '52'}"
EDIT,"Editas Medicine, Inc.",http://www.editasmedicine.com,,,89,"Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.","{'name': 'Ms. Katrine S. Bosley', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '672.75k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Charles  Albright Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '180.84k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. Gerald  Cox M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '100k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Feng  Zhang Ph.D.', 'title': 'Co-Founder and Scientific Advisory Board Member', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. George M. Church Ph.D.', 'title': 'Co-Founder and Scientific Advisory Board Member', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}"
EGRX,"Eagle Pharmaceuticals, Inc.",http://www.eagleus.com,N/A,N/A,N/A,"Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.","{'name': 'Mr. Scott L. Tarriff', 'title': 'Chief Exec. Officer and Director', 'pay': '1.86M', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. David M. Pernock', 'title': 'Pres and Chief Commercial Officer', 'pay': '47.5k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. Steven L. Krill Ph.D.', 'title': 'Chief Scientific Officer and Exec. VP', 'pay': '646.55k', 'exercised': '3.78M', 'age': '59'}","{'name': 'Dr. Adrian  Hepner M.D., Ph.D.', 'title': 'Chief Medical Officer and Exec. VP', 'pay': '1.27M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Pete A. Meyers MBA', 'title': 'Chief Financial Officer and Principal Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '48'}"
ENDP,Endo International plc,http://www.endo.com,N/A,N/A,N/A,"Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womens health, and cardiovascular disease markets. The companys U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating Peyronies and Dupuytrens contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womens health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.","{'name': 'Mr. Paul V. Campanelli', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.72M', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Blaise  Coleman', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '676.69k', 'exercised': 'N/A', 'age': '43'}","{'name': 'Mr. Terrance J. Coughlin', 'title': 'Chief Operating Officer and Exec. VP', 'pay': '879.57k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Matthew Joseph Maletta', 'title': 'Chief Legal Officer and Exec. VP', 'pay': '746.43k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Daniel A. Rudio', 'title': 'Chief Accounting Officer, Sr. VP and Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ENTA,"Enanta Pharmaceuticals, Inc.",http://www.enanta.com,Healthcare,Biotechnology,89,"Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companys research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.","{'name': 'Dr. Jay R. Luly Ph.D.', 'title': 'Chief Exec. Officer, Pres & Director', 'pay': '867.84k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Paul J. Mellett Jr.', 'title': 'Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer', 'pay': '513.18k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Dr. Yat Sun Or Ph.D.', 'title': 'Sr. VP-R&D and Chief Scientific Officer', 'pay': '564.64k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Mr. Nathaniel S. Gardiner J.D.', 'title': 'Sr. VP, Gen. Counsel & Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}","{'name': 'Dr. Timothy D. Ocain Ph.D.', 'title': 'Sr. VP of New Product Strategy & Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '60'}"
EPZM,"Epizyme, Inc.",http://www.epizyme.com,N/A,N/A,N/A,"Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Celgene RIVOT Ltd., Genentech Inc., Glaxo Group Limited, and US Oncology Research, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Robert B. Bazemore Jr.', 'title': 'Chief Exec. Officer, Pres, Sec. and Director', 'pay': '786.24k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. H. Robert Horvitz Ph.D., M.D.', 'title': 'Co-Founder and Chairman of the Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Yi  Zhang Ph.D.', 'title': 'Scientific Co-Founder and Member of The Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Suzanne  Fleming', 'title': 'Principal Accounting Officer, Sr. VP of Fin. & Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Matthew E. Ros', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}"
ESPR,"Esperion Therapeutics, Inc.",http://www.esperion.com,N/A,N/A,N/A,"Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.","{'name': 'Mr. Timothy M. Mayleben MBA', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '796.44k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBA', 'title': 'Chief Operating Officer and Exec. VP of R&D', 'pay': '487k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. Mary P. McGowan M.D.', 'title': 'Chief Medical Officer', 'pay': '481.36k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Roger S. Newton Ph.D., FAHA, FACN', 'title': 'Scientific Advisor and Director', 'pay': '358.58k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Mr. Richard B. Bartram', 'title': 'VP of Fin. and Corp. Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
EXEL,"Exelixis, Inc.",http://www.exelixis.com,Healthcare,Biotechnology,287,"Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companys products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.","{'name': 'Dr. Stelios  Papadopoulos Ph.D.', 'title': 'Co-Founder & Chairman', 'pay': 'N/A', 'exercised': 'N/A', 'age': '69'}","{'name': 'Dr. Michael M. Morrissey Ph.D.', 'title': 'CEO, Pres & Director', 'pay': '1.65M', 'exercised': '1.2M', 'age': '56'}","{'name': 'Mr. Christopher J. Senner', 'title': 'Exec. VP, CFO & Principal Accounting Officer', 'pay': '844.62k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Peter  Lamb Ph.D.', 'title': 'Exec. VP of Scientific Strategy & Chief Scientific Officer', 'pay': '720.25k', 'exercised': '1.35M', 'age': '56'}","{'name': 'Mr. Jeffrey J. Hessekiel J.D.', 'title': 'Exec. VP, Gen. Counsel & Sec.', 'pay': '760k', 'exercised': '956k', 'age': '48'}"
FGEN,"FibroGen, Inc.",http://www.fibrogen.com,Healthcare,Biotechnology,364,"FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.","{'name': 'Mr. Thomas B. Neff', 'title': 'Founder, Chairman & CEO', 'pay': '1.42M', 'exercised': '5.3M', 'age': '64'}","{'name': 'Mr. Pat  Cotroneo', 'title': 'VP of Fin. & CFO', 'pay': '690.75k', 'exercised': '141.64k', 'age': '54'}","{'name': 'Dr. K. Peony Yu M.D.', 'title': 'Chief Medical Officer', 'pay': '725.97k', 'exercised': '178.61k', 'age': '56'}","{'name': 'Dr. Barry A. Berkowitz Ph.D.', 'title': 'Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Michael J. Martinelli Ph.D.', 'title': 'VP of Technical Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
FLXN,"Flexion Therapeutics, Inc.",http://www.flexiontherapeutics.com,N/A,N/A,N/A,"Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.","{'name': 'Dr. Michael D. Clayman M.D.', 'title': 'Co-Founder, Pres, CEO, Principal Financial & Accounting Officer and Director', 'pay': '853.62k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. Neil  Bodick M.D., Ph.D.', 'title': 'Co-Founder & Chief Scientific Officer', 'pay': '604.41k', 'exercised': 'N/A', 'age': '70'}","{'name': 'Mr. Frederick W. Driscoll', 'title': 'Advisor', 'pay': '526.54k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Scott  Young', 'title': 'Sr. Director of Corp. Communications & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Carolyn Beaty Scimemi Esq.', 'title': 'Chief Compliance Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
FMI,"Foundation Medicine, Inc.",http://www.foundationmedicine.com,Healthcare,Medical Laboratories & Research,535,"Foundation Medicine, Inc. provides various molecular information products in the United States. The companys molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patients individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with WuXi PharmaTech Inc.; F. Hoffmann-La Roche Ltd.; and Genentech, Inc. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.","{'name': 'Dr. Steven  Kafka Ph.D.', 'title': 'Pres & COO', 'pay': '630.77k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Alexis  Borisy A.M.', 'title': 'Co-Founder, Founding Advisor & Independent Director', 'pay': '114k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Troy  Cox', 'title': 'CEO & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Jason  Ryan', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}","{'name': 'Dr. Phil  Stephens Ph.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
FOLD,"Amicus Therapeutics, Inc.",http://www.amicusrx.com,Healthcare,Biotechnology,263,"Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.","{'name': 'Mr. John F. Crowley', 'title': 'Chairman and Chief Exec. Officer', 'pay': '1.72M', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Bradley L. Campbell', 'title': 'Pres and Chief Operating Officer', 'pay': '657.99k', 'exercised': 'N/A', 'age': '42'}","{'name': 'Mr. William D. Baird III', 'title': 'Chief Financial Officer', 'pay': '543.52k', 'exercised': '19.43k', 'age': '46'}","{'name': 'Dr. Hung   Do Ph.D.', 'title': 'Chief Science Officer', 'pay': '502.32k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Jay A. Barth M.D.', 'title': 'Chief Medical Officer', 'pay': '782.29k', 'exercised': 'N/A', 'age': '54'}"
FOMX,Foamix Pharmaceuticals Ltd.,http://www.foamix.co.il,N/A,N/A,N/A,"Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Sebela Pharmaceuticals Inc.; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.","{'name': 'Mr. David T. Domzalski', 'title': 'Pres of Foamix Pharmaceuticals Inc', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Dov  Tamarkin Ph.D.', 'title': 'Co-Founder & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Meir  Eini', 'title': 'Co-Founder & Innovation Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Ilan  Hadar MBA', 'title': 'CFO & Country Mang.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Alvin D. Howard', 'title': 'VP of Regulatory Affairs - Foamix Pharmaceuticals Inc', 'pay': 'N/A', 'exercised': 'N/A', 'age': '63'}"
FPRX,"Five Prime Therapeutics, Inc.",http://www.fiveprime.com,Healthcare,Biotechnology,195,"Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The companys product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. The companys FP-1039 is in Phase Ib clinical trials to treat patients with malignant pleural mesothelioma. Its preclinical product candidates include FPA150, a CD8 T cell checkpoint inhibitor antibody; FPA154, a tetravalent agonistic antibody that activates glucocorticoid-induced tumor necrosis factor receptor; and FPT155, a CD80-Fc fusion protein, which modulates signaling pathways. The company has license and collaboration agreement with GlaxoSmithKline LLC, Bristol-Myers Squibb Company, and UCB Pharma S.A.; and license agreement with INBRX 110 LP, Galaxy Biotech, LLC, BioWa, Inc., and Lonza Sales AG. Five Prime Therapeutics, Inc. was founded in 2001 and is headquartered in South San Francisco, California.","{'name': 'Dr. Lewis T. Williams M.D., Ph.D.', 'title': 'Founder, Pres, CEO & Chairman', 'pay': '1.29M', 'exercised': '11.94M', 'age': '69'}","{'name': 'Mr. Marc L. Belsky', 'title': 'Sr. VP & CFO', 'pay': '625.12k', 'exercised': '2.66M', 'age': '63'}","{'name': 'Mr. Aron Marc Knickerbocker', 'title': 'COO & Director', 'pay': '795.03k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Kevin P. Baker Ph.D.', 'title': 'Sr. VP of Devel. Sciences', 'pay': '557.77k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Peder K. Jensen M.D.', 'title': 'Director and Advisor', 'pay': '68.75k', 'exercised': 'N/A', 'age': '63'}"
GBT,Global Blood Therapeutics Inc.,http://www.globalbloodtx.com,N/A,N/A,N/A,"Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.","{'name': 'Dr. Ted W. Love M.D.', 'title': 'Pres, CEO & Director', 'pay': '711.88k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Charles J. Homcy M.D.', 'title': 'Founder, Advisor and Director', 'pay': '41.29k', 'exercised': 'N/A', 'age': '69'}","{'name': 'Mr. Jeffrey S. Farrow', 'title': 'Chief Financial Officer', 'pay': '416.22k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Ms. Tricia Borga Suvari Esq.', 'title': 'Chief Legal Officer and Sec.', 'pay': '82.16k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. David R. Phillips Ph.D.', 'title': 'Founder and Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
GERN,Geron Corporation,http://www.geron.com,N/A,N/A,N/A,"Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.","{'name': 'Dr. John A. Scarlett M.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.07M', 'exercised': 'N/A', 'age': '66'}","{'name': 'Ms. Olivia Kyusuk Bloom', 'title': 'Chief Financial Officer, Exec. VP of Fin. and Treasurer', 'pay': '595.25k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Dr. Andrew J. Grethlein Ph.D.', 'title': 'Exec. VP of Devel. and Technical Operations', 'pay': '627.25k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Stephen N. Rosenfield J.D.', 'title': 'Exec. VP, Gen. Counsel and Corp. Sec.', 'pay': '498.3k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Mrs. Melissa A. Kelly Behrs', 'title': 'Exec. VP of Bus. Devel. and Portfolio & Alliance Management', 'pay': '587.48k', 'exercised': 'N/A', 'age': '53'}"
GHDX,"Genomic Health, Inc.",http://www.genomichealth.com,Healthcare,Medical Laboratories & Research,846,"Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreements with Epic Sciences, Inc. and BiocartisGroup NV. The company was founded in 2000 and is based in Redwood City, California.","{'name': 'Ms. Kimberly J. Popovits', 'title': 'Chairman, CEO & Pres', 'pay': '1.33M', 'exercised': '143.84k', 'age': '58'}","{'name': 'Dr. Steven  Shak M.D.', 'title': 'Co-Founder & Chief Scientific Officer', 'pay': '769.18k', 'exercised': '341.4k', 'age': '66'}","{'name': 'Mr. G. Bradley Cole', 'title': 'COO, CFO & Sec.', 'pay': '817.44k', 'exercised': '401.12k', 'age': '61'}","{'name': 'Mr. James J. Vaughn R.Ph.', 'title': 'Chief Commercial Officer', 'pay': '628.8k', 'exercised': '63.8k', 'age': '54'}","{'name': 'Dr. Frederic G. Pla Ph.D.', 'title': 'Chief Bus. & Product Devel. Officer', 'pay': '786k', 'exercised': 'N/A', 'age': '58'}"
GILD,"Gilead Sciences, Inc.",http://www.gilead.com,Healthcare,Biotechnology,"9,000","Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The companys products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.","{'name': 'Dr. John C. Martin', 'title': 'Exec. Chairman', 'pay': '3.76M', 'exercised': '80.81M', 'age': '65'}","{'name': 'Dr. John F. Milligan Ph.D.', 'title': 'Pres, CEO & Director', 'pay': '4.09M', 'exercised': '48.39M', 'age': '56'}","{'name': 'Ms. Robin L. Washington', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '1.85M', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Kevin B. Young CBE', 'title': 'Chief Operating Officer', 'pay': '1.82M', 'exercised': '1.12M', 'age': '59'}","{'name': 'Dr. Norbert W. Bischofberger Ph.D.', 'title': 'Exec. VP of R&D and Chief Scientific Officer', 'pay': '2.23M', 'exercised': 'N/A', 'age': '61'}"
GLPG,Galapagos NV,http://www.glpg.com,,,578,"Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companys clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, Crohns disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.","{'name': 'Mr. Onno  van de Stolpe', 'title': 'Co-Founder, Chief Exec. Officer, Managing Director and Exec. Director', 'pay': '942.21k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Bart  Filius MBA', 'title': 'COO & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Piet  Wigerinck Ph.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'Ms. Elizabeth  Goodwin', 'title': 'VP of Investor Relations & Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Veronique  Deiteren', 'title': 'Head of HR', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
GLYC,"GlycoMimetics, Inc.",http://www.glycomimetics.com,Healthcare,Biotechnology,42,"GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.","{'name': 'Mrs. Rachel K. King', 'title': 'CEO & Director', 'pay': '772.42k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Brian M. Hahn', 'title': 'CFO & Sec.', 'pay': '458.38k', 'exercised': 'N/A', 'age': '43'}","{'name': 'Dr. John L. Magnani Ph.D.', 'title': 'Sr. VP of Research, Chief Scientific Officer & Director', 'pay': '529.58k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Dr. Helen M. Thackray M.D., FAAP', 'title': 'Sr. VP of Clinical Devel. & Chief Medical Officer', 'pay': '577.27k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Henry  Flanner', 'title': 'VP of Technical Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
GRFS,"Grifols, S.A.",http://www.grifols.com,N/A,N/A,N/A,"Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.","{'name': 'Mr. Raimon Grifols  Roura', 'title': 'Co-Chief Exec. Officer and Exec. Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Ram??n Riera Roca', 'title': 'Exec. VP, Pres of Global Commercial Division and Exec. Director', 'pay': '1.07M', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Tom??s Dag?? Gelabert', 'title': 'Vice Sec. and External Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. V??ctor Grifols Deu', 'title': 'Co-Chief Exec. Officer and Exec. Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '40'}","{'name': 'Mr. Alfredo Arroyo Guerra', 'title': 'Chief Financial Officer and Corp. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': '59'}"
GTHX,"G1 Therapeutics, Inc.",http://www.g1therapeutics.com,N/A,N/A,N/A,"G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.","{'name': 'Dr. Mark A. Velleca M.D., Ph.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '546.6k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Rajesh K. Malik M.D., M.B., Ch.B.', 'title': 'Chief Medical Officer', 'pay': '411.15k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Barclay A. Phillips', 'title': 'CFO & Sr. VP of Corp. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Alexander D. Smith M.S.', 'title': 'VP of Technical Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Jay C. Strum Ph.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}"
GWPH,GW Pharmaceuticals plc,http://www.gwpharm.com,N/A,N/A,N/A,"GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It is also developing Sativex in Phase II trials in neuropathic pain. In addition, the companys product pipeline includes Epidiolex, which is in Phase III clinical development for the treatment of dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, adult epilepsy, and schizophrenia. It primarily operates Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.","{'name': 'Dr. Geoffrey W. Guy', 'title': 'Founder & Exec. Chairman', 'pay': 'N/A', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Justin D. Gover', 'title': 'CEO & Exec. Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Scott M. Giacobello', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. Christopher John Tovey BSc', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Douglas B. Snyder', 'title': 'Chief Legal Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}"
HALO,"Halozyme Therapeutics, Inc.",http://www.halozyme.com,Healthcare,Biotechnology,259,"Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The companys human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.","{'name': 'Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.', 'title': 'Pres, CEO & Director', 'pay': '1.25M', 'exercised': 'N/A', 'age': '54'}","{'name': 'Ms. Laurie D. Stelzer', 'title': 'Chief Financial Officer and Sr. VP', 'pay': '650.64k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Harry J. Leonhardt Esq.', 'title': 'Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.', 'pay': '619.76k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Mark J. Gergen J.D.', 'title': 'Consultant', 'pay': '222.53k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Michael J. LaBarre Ph.D.', 'title': 'Chief Scientific Officer and VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}"
HZNP,Horizon Pharma Public Limited Company,http://www.horizonpharma.com,N/A,N/A,N/A,"Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The companys marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.","{'name': 'Mr. Timothy P. Walbert', 'title': 'Chairman, Pres & CEO', 'pay': '2.28M', 'exercised': '172.93k', 'age': '50'}","{'name': 'Mr. Paul W. Hoelscher', 'title': 'Exec. VP & CFO', 'pay': '904.01k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Barry J. Moze', 'title': 'Exec. VP & Chief Admin. Officer', 'pay': '951.55k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Robert F. Carey', 'title': 'Chief Bus. Officer & Exec. VP', 'pay': '881.09k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. David A. Happel', 'title': 'Exec. VP of Commercial Devel. & Strategy', 'pay': '406.11k', 'exercised': 'N/A', 'age': '55'}"
ICPT,"Intercept Pharmaceuticals, Inc.",http://www.interceptpharma.com,N/A,N/A,N/A,"Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.","{'name': 'Dr. Mark  Pruzanski M.D.', 'title': 'Founder, Chief Exec. Officer, Pres & Director', 'pay': '1.04M', 'exercised': '7.64M', 'age': '49'}","{'name': 'Mr. Sandip S. Kapadia', 'title': 'CFO & Treasurer', 'pay': '282.06k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. David  Shapiro M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '688.88k', 'exercised': '295.76k', 'age': '63'}","{'name': 'Ms. Lisa  Bright B.Sc.', 'title': 'Pres of International', 'pay': '614.81k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Rachel L. McMinn Ph.D.', 'title': 'Advisor', 'pay': '592.51k', 'exercised': 'N/A', 'age': '44'}"
ILMN,"Illumina, Inc.",http://www.illumina.com,Healthcare,Biotechnology,"5,500","Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The companys sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has collaboration agreements with IBM Watson Health to access genome data interpretation by integrating Watson for genomics into Illuminas BaseSpace Sequence Hub and tumor sequencing process; and NRGene to develop new molecular breeding tools for cattle to support global food production. The company also has a co-development agreement with Munich Leukemia Laboratory GmbH and IBM Watson Health to build a cognitive technology prototype to help researchers improve leukemia treatment. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.","{'name': 'Mr. Jay T. Flatley', 'title': 'Exec. Chairman', 'pay': '991.87k', 'exercised': '20.45M', 'age': '64'}","{'name': 'Mr. Francis A. deSouza', 'title': 'CEO, Pres & Director', 'pay': '908.66k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Omead  Ostadan', 'title': 'Exec. VP of Operations, Products and Strategy', 'pay': '539.95k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Dr. Mostafa  Ronaghi Ph.D.', 'title': 'Chief Technology Officer and Sr. VP', 'pay': '451.24k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Marc A. Stapley', 'title': 'Chief Admin. Officer and Exec. VP', 'pay': '556.47k', 'exercised': 'N/A', 'age': '47'}"
IMGN,"ImmunoGen, Inc.",http://www.immunogen.com,Healthcare,Biotechnology,308,"ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.","{'name': 'Mr. Mark J. Enyedy', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '568.98k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. David B. Johnston', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '279.44k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Dr. Richard J. Gregory Ph.D.', 'title': 'Chief Scientific Officer and Exec. VP', 'pay': '312.48k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Anna  Berkenblit M.D., MM.Sc', 'title': 'Chief Medical Officer and VP', 'pay': '269.23k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Ms. Carol  Hausner', 'title': 'Exec. Director of Investor Relations & Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
IMMU,"Immunomedics, Inc.",http://www.immunomedics.com,Healthcare,Biotechnology,138,"Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.","{'name': 'Dr. David M. Goldenberg', 'title': 'Founder, Chief Patent Officer, Chief Scientific Officer & Director', 'pay': '779.44k', 'exercised': '1.21M', 'age': '79'}","{'name': 'Mr. Michael R. Garone', 'title': 'CFO, Principal Accounting Officer & VP of Fin.', 'pay': '4.62k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Michael F. Pehl', 'title': 'Pres, CEO & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'Ms. Phyllis  Parker', 'title': 'Director of Admin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Chau  Cheng', 'title': 'Sr. Director of Investor Relations & Corp. Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
INCR,"INC Research Holdings, Inc.",http://www.incresearch.com,N/A,N/A,N/A,"INC Research Holdings, Inc., a contract research organization, provides various clinical development services for the biopharmaceutical and medical device industries in North America, Europe, the Middle East and Africa, the Asia-Pacific, and Latin America. The company offers a range of services focusing on Phase I to Phase IV clinical trials in central nervous system, oncology, and other complex therapeutic areas. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, and regulatory and medical writing; and data services consisting of clinical data management, electronic data capture, and biostatistics. The companys services also comprise strategic and regulatory services, including strategic development services, regulatory consulting and submissions, clinical operations optimization, and pricing and reimbursement planning; and real world and late stage services, such as specialized support for patient registries, safety surveillance studies, prospective observational studies, health outcome research, patient reported outcomes, Phase IV effectiveness trials, and health economics studies and retrospective chart reviews. In addition, it offers functional services, such as data management, medical writing, safety/pharmacovigilance, site contracts, and investigator payments. INC Research Holdings, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.","{'name': 'Mr. Alistair  MacDonald', 'title': 'CEO & Director', 'pay': '1.35M', 'exercised': '524.52k', 'age': '48'}","{'name': 'Mr. Gregory S. Rush', 'title': 'Chief Financial Officer', 'pay': '894.46k', 'exercised': '1.84M', 'age': '51'}","{'name': 'Mr. Christopher L. Gaenzle', 'title': 'Chief Admin. Officer, Gen. Counsel & Sec.', 'pay': '821.83k', 'exercised': '861.66k', 'age': '51'}","{'name': 'Dr. Michael  Gibertini Ph.D.', 'title': 'Pres of Clinical Devel. for Therapeutic Bus. Units', 'pay': 'N/A', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. Judith  Ng-Cashin M.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
INCY,Incyte Corporation,http://www.incyte.com,Healthcare,Biotechnology,980,"Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The companys clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the companys clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.","{'name': 'Mr. Herv??  Hoppenot', 'title': 'Chairman, CEO & Pres', 'pay': '2.28M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. David W. Gryska MBA', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '903.11k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Dr. Reid M. Huber Ph.D.', 'title': 'Chief Scientific Officer and Exec. VP', 'pay': '798.32k', 'exercised': '1.22M', 'age': '45'}","{'name': 'Dr. Wenqing  Yao Ph.D.', 'title': 'Exec. VP of Discovery Medicinal and Process Chemistry', 'pay': '719.59k', 'exercised': '367.43k', 'age': '54'}","{'name': 'Dr. Steven H. Stein M.D.', 'title': 'Chief Medical Officer and Sr. VP', 'pay': '724.61k', 'exercised': 'N/A', 'age': '50'}"
INO,"Inovio Pharmaceuticals, Inc.",http://www.inovio.com,N/A,N/A,N/A,"Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.","{'name': 'Dr. J. Joseph Kim Ph.D.', 'title': 'CEO, Pres & Director', 'pay': '1.03M', 'exercised': '1.51M', 'age': '48'}","{'name': 'Mr. Peter D. Kies', 'title': 'Chief Financial Officer', 'pay': '538.36k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Niranjan Y. Sardesai Ph.D.', 'title': 'Chief Operating Officer', 'pay': '575.44k', 'exercised': '90.74k', 'age': '49'}","{'name': 'Dr. Mark L. Bagarazzi M.D.', 'title': 'Chief Medical Officer', 'pay': '576.45k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Ms. Jessica C. Lee MS, MPH', 'title': 'VP of Clinical Operations & Compliance', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
INSM,Insmed Incorporated,http://www.insmed.com,N/A,N/A,N/A,"Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companys lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.","{'name': 'Mr. William H. Lewis', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '887.95k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Ms. Christine A. Pellizzari', 'title': 'Gen. Counsel and Corp. Sec.', 'pay': '572.26k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Ms. S. Nicole Schaeffer', 'title': 'Sr. VP of HR & Corp. Services', 'pay': '459.25k', 'exercised': '343.21k', 'age': '49'}","{'name': 'Dr. Eugene J. Sullivan M.D., FCCP', 'title': 'Chief Product Strategy Officer', 'pay': '593.08k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Andrew T. Drechsler', 'title': 'Advisor', 'pay': '538.76k', 'exercised': '395.42k', 'age': '45'}"
INSY,"INSYS Therapeutics, Inc.",http://www.insysrx.com,N/A,N/A,N/A,"Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.","{'name': 'Mr. Franc  Del Fosse', 'title': 'Gen. Counsel and Corp. Sec.', 'pay': '307.9k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Saeed  Motahari', 'title': 'Pres, CEO & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Andrew G. Long', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. B. Sanga Emmanuel', 'title': 'VP & Chief Compliance Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Joe  McGrath', 'title': 'Sr. Director of Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
INVA,"Innoviva, Inc.",http://www.inva.com,N/A,N/A,N/A,"Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.","{'name': 'Mr. Michael W. Aguiar', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.44M', 'exercised': 'N/A', 'age': '51'}","{'name': ""Mr. Eric  d'Esparbes"", 'title': 'Chief Financial Officer and Sr. VP', 'pay': '686.28k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Theodore J. Witek Jr., MBA, Ph.D.', 'title': 'Chief Scientific Officer and Sr. VP', 'pay': '696.7k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Michael Eric Faerm', 'title': 'Chief Bus. Officer and Sr. VP', 'pay': '869.01k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Jeffrey A. Hagenah Ph.D.', 'title': 'Chief Patent Counsel and VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
IONS,"Ionis Pharmaceuticals, Inc.",http://www.ionispharma.com,,,435,"Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.","{'name': 'Dr. Stanley T. Crooke M.D., Ph.D.', 'title': 'Founder, Exec. Chairman, Chief Exec. Officer and Pres', 'pay': '2.06M', 'exercised': '3.57M', 'age': '72'}","{'name': 'Dr. Brett P. Monia Ph.D.', 'title': 'Founder and Sr. VP of Drug Discovery & Corp. Devel.', 'pay': '786.67k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Ms. Elizabeth L. Hougen', 'title': 'Chief Financial Officer and Sr. VP of Fin.', 'pay': '735.75k', 'exercised': '319.89k', 'age': '55'}","{'name': 'Ms. B. Lynne Parshall Esq., J.D.', 'title': 'Chief Operating Officer and Director', 'pay': '1.54M', 'exercised': '808.66k', 'age': '63'}","{'name': ""Mr. Patrick R. O'Neil Esq."", 'title': 'Chief Compliance Officer, Sr. VP of Legal, Gen. Counsel and Corp. Sec.', 'pay': '779.71k', 'exercised': '168.21k', 'age': '43'}"
IOVA,"Iovance Biotherapeutics, Inc.",http://www.iovance.com,N/A,N/A,N/A,"Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The companys lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patients TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas MD Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.","{'name': 'Dr. Maria  Fardis Ph.D., MBA', 'title': 'CEO, Pres & Director', 'pay': '441.67k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Michael T. Lotze M.D.', 'title': 'Chief Scientific Officer and VP of R&D', 'pay': '423.27k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Dr. Elma S. Hawkins Ph.D., MBA', 'title': 'Advisor to the Board', 'pay': '465.39k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Timothy E. Morris CPA', 'title': 'CFO & Principal Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Frederick G. Vogt Ph.D., Esq.', 'title': 'Gen. Counsel', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
IRWD,"Ironwood Pharmaceuticals, Inc.",http://www.ironwoodpharma.com,Healthcare,Drugs - Generic,674,"Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.","{'name': 'Dr. Peter M. Hecht Ph.D.', 'title': 'Co-Founder, Chief Exec. Officer and Director', 'pay': '108.06k', 'exercised': '2.76M', 'age': '53'}","{'name': 'Dr. Mark G. Currie Ph.D.', 'title': 'Chief Scientific Officer, Pres of R&D and Sr. VP', 'pay': '763.04k', 'exercised': '6.08M', 'age': '62'}","{'name': 'Ms. Halley E. Gilbert Esq.', 'title': 'Sr. VP, Chief Legal Officer & Sec.', 'pay': '711.04k', 'exercised': '315.6k', 'age': '47'}","{'name': 'Mr. Thomas A. McCourt', 'title': 'Chief Commercial Officer and Sr. VP of Marketing & Sales', 'pay': '731.04k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Brian M. Cali Ph.D.', 'title': 'Co-Founder and Sr. VP of R&D Strategy & External Innovation', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
ITCI,"Intra-Cellular Therapies, Inc.",http://www.intracellulartherapies.com,N/A,N/A,N/A,"Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinsons and Alzheimers disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.","{'name': 'Dr. Sharon  Mates Ph.D.', 'title': 'Co-Founder, Chairman, CEO & Pres', 'pay': '1.1M', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. Lawrence J. Hineline CPA', 'title': 'VP of Fin., CFO, Treasurer & Assistant Sec.', 'pay': '568.74k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Dr. Robert E. Davis Ph.D.', 'title': 'Sr. VP & Chief Scientific Officer', 'pay': '569.47k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Mr. Michael I. Halstead J.D.', 'title': 'Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec.', 'pay': '626.87k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Dr. Kimberly E. Vanover Ph.D.', 'title': 'Sr. VP of Clinical Devel.', 'pay': '533.23k', 'exercised': '258.12k', 'age': '52'}"
JAZZ,Jazz Pharmaceuticals Public Limited Company,http://www.jazzpharma.com,N/A,N/A,N/A,"Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinsons disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.","{'name': 'Mr. Bruce C. Cozadd', 'title': 'Co-Founder, Exec. Chairman & CEO', 'pay': '1.84M', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Matthew P. Young', 'title': 'Exec. VP & CFO', 'pay': '817.79k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Russell J. Cox', 'title': 'Exec. VP & COO', 'pay': '889.98k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Ms. Suzanne Sawochka Hooper', 'title': 'Exec. VP & Gen. Counsel', 'pay': '826.78k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Karen L. Smith M.D., PH.D., M.B.A., L.L.M', 'title': 'Chief Medical Officer and Exec. VP of R&D', 'pay': '745.85k', 'exercised': 'N/A', 'age': '49'}"
JNCE,"Jounce Therapeutics, Inc.",http://www.jouncetx.com,,,113,"Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. The company is also developing JTX-4014, an anti-PD-1 antibody. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.","{'name': 'Dr. Richard  Murray Ph.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '641.86k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Ms. Kimberlee Cobleigh Drapkin CPA', 'title': 'Chief Financial Officer and Treasurer', 'pay': '408.79k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Dr. Elizabeth G. Trehu M.D.', 'title': 'Chief Medical Officer', 'pay': '534.26k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. James P. Allison Ph.D.', 'title': 'Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Thomas F. Gajewski M.D., Ph.D.', 'title': 'Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
JUNO,"Juno Therapeutics, Inc.",http://www.junotherapeutics.com,N/A,N/A,N/A,"Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory (r/r) B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL. The companys CD22 product candidate comprise JCAR018, which is in Phase I trial for pediatric and young adult patients with CD22-positive r/r ALL or r/r NHL. Its additional product candidates include CD171, a cell-surface adhesion molecule to treat neuroblastoma; Lewis Y for the treatment of lung cancer; JCAR023, which is in Phase I trial for patients with refractory or recurrent pediatric neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers; and IL13ra2 for treating glioblastoma. Juno Therapeutics, Inc. has collaboration agreements with Celgene Corporation, Fate Therapeutics, Inc., Editas Medicine, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.","{'name': 'Mr. Hans E. Bishop', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Director', 'pay': '683.89k', 'exercised': '7.59M', 'age': '54'}","{'name': 'Dr. Richard D. Klausner M.D.', 'title': 'Co-Founder and Director', 'pay': '250k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Mr. Robert T. Nelsen', 'title': 'Co-Founder and Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Steven D. Harr M.D.', 'title': 'Chief Financial Officer and Head of Corp. Devel.', 'pay': '536.79k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Dr. Hyam I. Levitsky M.D.', 'title': 'Chief Scientific Officer and Exec. VP of Research', 'pay': '594.4k', 'exercised': 'N/A', 'age': '60'}"
KALA,"Kala Pharmaceuticals, Inc.",http://www.kalarx.com,N/A,N/A,N/A,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The companys product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.","{'name': 'Mr. Mark T. Iwicki', 'title': 'Exec. Chairman, CEO & Pres', 'pay': '728.34k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Hongming  Chen Sc.D.', 'title': 'Chief Scientific Officer', 'pay': '453.74k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Dr. Kim  Brazzell Ph.D.', 'title': 'Chief Medical Officer', 'pay': '484.43k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. Justin  Hanes Ph.D.', 'title': 'Founder & Chair of the Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Mary  Reumuth CPA', 'title': 'CFO & Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '43'}"
KPTI,Karyopharm Therapeutics Inc.,http://www.karyopharm.com,N/A,N/A,N/A,"Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkins lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.","{'name': 'Dr. Michael G. Kauffman M.D., Ph.D.', 'title': 'Co-Founder, Chief Exec. Officer and Director', 'pay': '773.46k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Sharon  Shacham Ph.D., M.B.A.', 'title': 'Co-Founder, Co-Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer', 'pay': '592.26k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Justin A. Renz CPA, MST, MBA', 'title': 'Advisor', 'pay': '485.36k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Mansoor Raza Mirza M.D.', 'title': 'Clinical Consultant, Director and Member of Scientific Advisory Board', 'pay': '254.38k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Michael F. Falvey', 'title': 'Exec. VP, CFO & Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '59'}"
KURA,"Kura Oncology, Inc.",http://www.kuraoncology.com,N/A,N/A,N/A,"Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companys lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.","{'name': 'Dr. Troy Edward Wilson Ph.D., J.D.', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '653.98k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Ms. Annette  North Esq., LLB', 'title': 'Sr. VP and Gen. Counsel', 'pay': '459.34k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Antonio  Gualberto M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '527.11k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Ms. Heidi  Henson CPA', 'title': 'Chief Financial Officer and Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Yi  Liu Ph.D.', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}"
LGND,Ligand Pharmaceuticals Incorporated,http://www.ligand.com,N/A,N/A,N/A,"Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companys partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.","{'name': 'Mr. John L. Higgins', 'title': 'Chief Exec. Officer and Exec. Director', 'pay': '967.36k', 'exercised': '469.5k', 'age': '47'}","{'name': 'Mr. Matthew W. Foehr', 'title': 'Pres and Chief Operating Officer', 'pay': '697.43k', 'exercised': '2.6M', 'age': '44'}","{'name': 'Mr. Matthew  Korenberg', 'title': 'Chief Financial Officer, Principal Accounting Officer and VP of Fin.', 'pay': '505.12k', 'exercised': 'N/A', 'age': '42'}","{'name': 'Mr. Charles S. Berkman J.D.', 'title': 'VP, Gen. Counsel and Sec.', 'pay': '471.86k', 'exercised': '2.08M', 'age': '48'}","{'name': 'Ms. Audrey  Warfield-Graham', 'title': 'VP of HR', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
LMNX,Luminex Corporation,http://www.luminexcorp.com,Healthcare,Medical Instruments & Supplies,936,"Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The companys products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, and ARIES GBS assays; Verigene test cartridges; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; pharmacogenetics family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.","{'name': 'Mr. Nachum  Shamir', 'title': 'Pres, CEO & Director', 'pay': '1.64M', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Harriss T. Currie', 'title': 'CFO, Sr. VP of Fin. & Treasurer', 'pay': '667.03k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Richard W. Rew II', 'title': 'Sr. VP of Legal, Gen. Counsel & Corp. Sec.', 'pay': '569.6k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Todd C. Bennett', 'title': 'Sr. VP of Global Sales & Customer Operations', 'pay': '537.28k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. Randall J. Myers', 'title': 'Sr. VP of Global Manufacturing & Quality', 'pay': '506.09k', 'exercised': 'N/A', 'age': '55'}"
LOXO,"Loxo Oncology, Inc.",http://www.loxooncology.com,N/A,N/A,N/A,"Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The companys preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.","{'name': 'Dr. Joshua H. Bilenker M.D.', 'title': 'Founder, Chief Exec. Officer, Pres and Director', 'pay': '788k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Ms. Jennifer  Burstein M.B.A. CPA', 'title': 'VP of Fin. & Principal Financial Officer', 'pay': '408k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Jacob S. Van Naarden', 'title': 'Chief Bus. Officer', 'pay': '477.12k', 'exercised': 'N/A', 'age': '32'}","{'name': 'Dr. Lori Anne Kunkel M.D.', 'title': 'Consultant and Director', 'pay': '35k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Ms. Sara  Slifka', 'title': 'VP of Bus. Operations & Program Management', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
LXRX,"Lexicon Pharmaceuticals, Inc.",http://www.lexpharma.com,Healthcare,Biotechnology,168,"Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.","{'name': 'Mr. Lonnel  Coats', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.05M', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Jeffrey L. Wade J.D.', 'title': 'Chief Financial Officer and Exec. VP of Corp. & Admin. Affairs', 'pay': '610.38k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Alan J. Main Ph.D.', 'title': 'Exec. VP of Commercial Supply Operations', 'pay': '518.41k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Dr. Pablo  Lapuerta M.D.', 'title': 'Chief Medical Officer and Exec. VP', 'pay': '541.51k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Praveen  Tyle Ph.D.', 'title': 'Exec. VP of R&D', 'pay': '487.38k', 'exercised': 'N/A', 'age': '57'}"
MCRB,"Seres Therapeutics, Inc.",http://www.serestherapeutics.com,N/A,N/A,N/A,"Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.","{'name': 'Dr. Roger James Pomerantz M.D., F.A.C.P.', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '967.13k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Thomas J. DesRosier Esq., J.D.', 'title': 'Chief Legal Officer, Exec. VP and Sec.', 'pay': '375.2k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Eric D. Shaff', 'title': 'Chief Financial Officer and Exec. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': '42'}","{'name': 'Dr. John G. Aunins Ph.D.', 'title': 'Chief Technology Officer and Exec. VP of Bioprocess & Manufacturing', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. David N. Cook Ph.D.', 'title': 'Chief Scientific Officer and Exec. VP of R&D', 'pay': 'N/A', 'exercised': 'N/A', 'age': '60'}"
MDCO,The Medicines Company,http://www.themedicinescompany.com,Healthcare,Drugs - Generic,410,"The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms. The companys approved products include Adenosine, Amiodarone, Esmolol, and Milrinone for acute cardiovascular; Azithromycin and Clindamycin for serious infectious disease; and Haloperidol, Midazolam, Ondansetron, and Rocuronium for surgery and perioperative treatment. Its research and development stage products comprise Carbavance, an antibiotic agent that has completed Phase III development stage for the treatment of hospitalized patients with serious gram-negative bacterial infections; Inclisiran, a synthesis inhibitor for the potential treatment of hypercholesterolemia; and MDCO-700, an intravenous anesthetic agent developed for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures. The Medicines Company has a collaboration agreement with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.","{'name': 'Dr. Fredric N. Eshelman Pharm.D.', 'title': 'Exec. Chairman', 'pay': '78.29k', 'exercised': 'N/A', 'age': '68'}","{'name': 'Dr. Clive A. Meanwell M.D., Ph.D.', 'title': 'CEO & Director', 'pay': '1.75M', 'exercised': '824.05k', 'age': '59'}","{'name': 'Mr. Stuart Anthony Kingsley MBA', 'title': 'Pres and Chief Operating Officer', 'pay': '723.78k', 'exercised': 'N/A', 'age': '53'}","{'name': ""Mr. William B. O'Connor"", 'title': 'Chief Financial Officer', 'pay': '863.37k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Stephen M. Rodin J.D.', 'title': 'Exec. VP, Gen. Counsel and Sec.', 'pay': '798.42k', 'exercised': 'N/A', 'age': '41'}"
MEDP,"Medpace Holdings, Inc.",http://www.medpace.com,,,"2,500","Medpace Holdings, Inc. provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its services include medical affairs, clinical trial management, study feasibility, study start-up, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.","{'name': 'Dr. August James Troendle M.D.', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '478.98k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Jesse J. Geiger BBA, CPA', 'title': 'Chief Financial Officer and Chief Operating Officer of Laboratory Operations', 'pay': '550.67k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Ms. Susan E. Burwig MA, BSN', 'title': 'Exec. VP of Operations', 'pay': '614.08k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Stephen P. Ewald J.D.', 'title': 'Gen. Counsel and Corp. Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Todd  Meyers', 'title': 'VP of Bus. Devel. and Marketing', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
MGNX,"MacroGenics, Inc.",http://www.macrogenics.com,Healthcare,Biotechnology,318,"MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The companys advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate. In addition, the companys products include MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. It has collaboration and license agreements with Janssen Biotech, Inc.; Les Laboratoires Servier and Institut de Recherches Servier; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.","{'name': 'Dr. Scott  Koenig M.D., Ph.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '783.55k', 'exercised': '1.92M', 'age': '65'}","{'name': 'Mr. James  Karrels', 'title': 'Chief Financial Officer, Sr. VP and Sec.', 'pay': '457.46k', 'exercised': '185.2k', 'age': '50'}","{'name': 'Dr. Ezio  Bonvini M.D.', 'title': 'Chief Scientific Officer and Sr. VP of Research', 'pay': '492.64k', 'exercised': '632.73k', 'age': '63'}","{'name': 'Mr. Eric Blasius Risser', 'title': 'Chief Bus. Officer and Sr. VP of Bus. Devel. & Portfolio Management', 'pay': '474.49k', 'exercised': '37.15k', 'age': '44'}","{'name': 'Dr. Jon M. Wigginton M.D.', 'title': 'Chief Medical Officer and Sr. VP of Clinical Devel.', 'pay': '565.91k', 'exercised': '1.13M', 'age': '55'}"
MNKD,MannKind Corporation,http://www.mannkindcorp.com,Healthcare,Biotechnology,153,"MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is headquartered in Westlake Village, California.","{'name': 'Dr. Michael E. Castagna Pharm.D.', 'title': 'CEO & Director', 'pay': '378.41k', 'exercised': 'N/A', 'age': '40'}","{'name': 'Dr. David B. Thomson Ph.D., J.D.', 'title': 'Corp. VP, Gen. Counsel & Corp. Sec.', 'pay': '458.68k', 'exercised': '424.8k', 'age': '50'}","{'name': 'Mr. Steven  Binder', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Joseph  Kocinsky', 'title': 'Chief Technology Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}","{'name': 'Ms. Courtney  Barton', 'title': 'Chief Compliance Officer and VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
MNTA,"Momenta Pharmaceuticals, Inc.",http://www.momentapharma.com,Healthcare,Drugs - Generic,290,"Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The companys complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The companys novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy; M281, a fully-human monoclonal antibody that blocks the neonatal Fc receptor; and M230, a selective immunomodulator of Fc receptors candidate. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Craig A. Wheeler', 'title': 'Chief Exec. Officer, Pres and Exec. Director', 'pay': '1.27M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Ganesh Venkataraman Kaundinya Ph.D.', 'title': 'Co-Founder, COO, Chief Scientific Officer & Sr. VP', 'pay': '648.27k', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Scott M. Storer', 'title': 'Chief Financial Officer, Sr. VP & Treasurer', 'pay': '40.53k', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Bruce A. Leicher J.D.', 'title': 'Sr. VP, Gen. Counsel and Corp. Sec.', 'pay': '620.78k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. Young T. Kwon Ph.D.', 'title': 'Sr. VP of Corp. Devel. & Strategy', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
MRNS,"Marinus Pharmaceuticals, Inc.",http://www.marinuspharma.com,N/A,N/A,N/A,"Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.","{'name': 'Mr. Christopher Michael Cashman', 'title': 'Exec. Chairman, Chief Exec. Officer and Pres', 'pay': '613.1k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Edward F. Smith', 'title': 'CFO, VP, Treasurer & Sec.', 'pay': '433.5k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Ms. Lisa M. Caperelli', 'title': 'Exec. Director of Investor & Strategic Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Kimberly A. McCormick PharmD', 'title': 'Head of Regulatory Affairs', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Lorianne K. Masuoka M.D.', 'title': 'Chief Medical Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}"
MRSN,"Mersana Therapeutics, Inc.",http://www.mersana.com,,,N/A,"Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.","{'name': 'Mr. David M. Mott', 'title': 'Exec. Chairman', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'Ms. Anna  Protopapas', 'title': 'Pres, CEO & Director', 'pay': '599.77k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Timothy B. Lowinger Ph.D.', 'title': 'Sr. VP & Chief Scientific Officer', 'pay': '495.59k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Donald A. Bergstrom M.D., Ph.D.', 'title': 'Sr. VP & Chief Medical Officer', 'pay': '492.59k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Mikhail  Papisov Ph.D.', 'title': 'Co-Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
MYGN,"Myriad Genetics, Inc.",http://www.myriad.com,Services,Research Services,"2,400","Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.","{'name': 'Mr. Mark Christopher Capone', 'title': 'Pres, CEO & Director', 'pay': '1.54M', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. R. Bryan Riggsbee', 'title': 'CFO & Treasurer', 'pay': '590.53k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Jerry S. Lanchbury Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '706.94k', 'exercised': '2.95M', 'age': '58'}","{'name': 'Mr. Richard M. Marsh Esq.', 'title': 'Exec. VP, Gen. Counsel & Sec.', 'pay': '708.87k', 'exercised': '1.48M', 'age': '59'}","{'name': 'Mr. Alexander  Ford', 'title': 'Pres of Myriad Genetic Laboratories, Inc.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}"
MYL,Mylan N.V.,http://www.mylan.com,N/A,N/A,N/A,"Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.","{'name': 'Ms. Heather  Bresch', 'title': 'CEO & Exec. Director', 'pay': '4.27M', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Rajiv  Malik', 'title': 'Pres & Exec. Director', 'pay': '2.85M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Kenneth S. Parks', 'title': 'Chief Financial Officer', 'pay': '1.44M', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Anthony  Mauro', 'title': 'Chief Commercial Officer', 'pay': '1.87M', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Paul B. Campbell', 'title': 'Chief Accounting Officer, Sr. VP and Corp. Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
MYOK,"MyoKardia, Inc.",http://www.myokardia.com,,,98,"MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, a product candidate that is intended to increase cardiac muscle contractility to normal levels in genetic DCM patients through a different mechanism than that of MYK-491; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. The company has a strategic collaboration with Sanofi S.A. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.","{'name': 'Mr. Tassos Anastasios Gianakakos', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '680.64k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Jake B. Bauer', 'title': 'Principal Financial Officer, Sr. VP of Fin. & Corp. Devel. and Assistant Sec.', 'pay': '403.84k', 'exercised': 'N/A', 'age': '39'}","{'name': 'Dr. Marc  Semigran M.D.', 'title': 'Chief Medical Officer', 'pay': '237.55k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. Charles J. Homcy M.D.', 'title': 'Advisor', 'pay': '43.44k', 'exercised': 'N/A', 'age': '70'}","{'name': 'Dr. Eric J. Topol M.D.', 'title': 'Advisor', 'pay': '53.5k', 'exercised': 'N/A', 'age': '64'}"
NBIX,"Neurocrine Biosciences, Inc.",http://www.neurocrine.com,Healthcare,Drugs - Generic,400,"Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The companys lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womens health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinsons disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the companys research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for womens and mens health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL  Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinsons disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.","{'name': 'Dr. Kevin C. Gorman Ph.D.', 'title': 'CEO & Director', 'pay': '972.52k', 'exercised': '337.25k', 'age': '59'}","{'name': ""Dr. Christopher F. O'Brien M.D."", 'title': 'Chief Medical Officer', 'pay': '758.71k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. Haig P. Bozigian Ph.D.', 'title': 'Chief Devel. Officer', 'pay': '632.78k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Eric S. Benevich', 'title': 'Chief Commercial Officer', 'pay': '607.86k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Timothy P. Coughlin CPA', 'title': 'Exec. Officer', 'pay': '666.37k', 'exercised': 'N/A', 'age': '50'}"
NBRV,Nabriva Therapeutics plc,http://www.nabriva.com,N/A,N/A,N/A,"Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companys product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.","{'name': 'Dr. Colin  Broom M.D.', 'title': 'CEO, Interim Chief Medical Officer & Director', 'pay': '658.64k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Dr. Elyse G. Seltzer M.D.', 'title': 'Consultant', 'pay': '473.52k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Gary L. Sender', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Steven P. Gelone Pharm. D', 'title': 'Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Thomas  Lembck', 'title': 'Chief Information Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
NEOS,"Neos Therapeutics, Inc.",http://www.neostx.com,N/A,N/A,N/A,"Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.","{'name': 'Dr. Vipin K. Garg Ph.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '555.49k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Richard I. Eisenstadt M.B.A.', 'title': 'Chief Financial Officer', 'pay': '375.27k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Thomas P. McDonnell', 'title': 'Chief Commercial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Russ  McMahen', 'title': 'VP of R&D', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Carolyn R. Sikes Ph.D.', 'title': 'VP of Clinical Affairs', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
NERV,"Minerva Neurosciences, Inc.",http://www.minervaneurosciences.com,N/A,N/A,N/A,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companys lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The company preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinsons disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.","{'name': 'Dr. R??my  Luthringer', 'title': 'Chief Exec. Officer and Director', 'pay': '680.15k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Geoffrey Robin Race FCMA, MBA', 'title': 'Exec. VP, CFO & Chief Bus. Officer', 'pay': '588.15k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Joseph  Reilly', 'title': 'Sr. VP & COO', 'pay': '461k', 'exercised': 'N/A', 'age': '43'}","{'name': 'Mr. Richard  Russell', 'title': 'Pres', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Frederick W. Ahlholm CPA', 'title': 'Sr. VP & Chief Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}"
NH,"NantHealth, Inc.",http://www.nanthealth.com,,,922,"NantHealth, Inc. operates as an evidence-based personalized healthcare company. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care for critical illnesses. It develops NantHealth solutions, an adaptive learning system, including molecular profiling solution, software, middleware, and hardware systems infrastructure that collects, indexes, analyzes, and interprets various molecular, clinical, operational, and financial data points derived from novel and traditional sources to enhance decision-making. The companys products include Genomic Proteomic Spectrometry (GPS) Cancer molecular profile that integrates whole genome and transcriptome sequencing, and quantitative proteomics; GPS Cancer Report, a clinical cancer platform; and eviti, a decision support oncology solution. It also develops GPS in rare diseases and chronic illnesses. In addition, the company offers Nant Operating System (NantOS) and NantOS apps that include proprietary methods and algorithms, including patient portal and health heritage NantOS apps, care coordination and real-time connectivity NantOS apps, Provider Portal NantOS App, Care Coordination NantOS App Suite, Referral Management NantOS App, and Secure Messaging NantOS App, as well as cancer genome browser for healthcare providers and payors, self-insured employers, and biopharmaceutical companies. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was founded in 2010 and is headquartered in Culver City, California. NantHealth, Inc. operates as a subsidiary of NantWorks, LLC.","{'name': 'Dr. Patrick  Soon-Shiong M.D., FRCS (C), FACS', 'title': 'CEO, Chairman & Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}","{'name': 'Mr. Paul A. Holt', 'title': 'Chief Financial Officer', 'pay': '469.88k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Ronald Allen Louks', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Brandon  Villery', 'title': 'VP & Gen. Counsel', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Charles  Hunt', 'title': 'VP of Marketing, Communications & User Experience', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
NK,"NantKwest, Inc.",http://www.nantkwest.com,Healthcare,Biotechnology,118,"NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companys proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.","{'name': 'Dr. Patrick  Soon-Shiong M.D., FRCS (C), FACS', 'title': 'Exec. Chairman and Chief Exec. Officer', 'pay': '602.31k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. Barry J. Simon M.D.', 'title': 'Pres, Chief Admin. Officer and Exec. Director', 'pay': '420.31k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Ms. Sonja  Nelson', 'title': 'Chief Accounting Officer', 'pay': '496.44k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Richard J. Tajak M.B.A.', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. David J. Pyrce M.B.A.', 'title': 'Chief Commercial Officer and Sr. VP of Innovation & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '61'}"
NKTR,Nektar Therapeutics,http://www.nektar.com,Healthcare,Biotechnology,468,"Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The companys drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). It has a research collaboration agreement with Takeda Pharmaceutical Company Limited to explore the anti-cancer activity of NKTR-214; and a strategic collaboration with Eli Lilly and Company to develop and commercialize NKTR-358. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.","{'name': 'Mr. Howard W. Robin', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '1.83M', 'exercised': '5.86M', 'age': '64'}","{'name': 'Mr. Gil M. Labrucherie J.D.', 'title': 'Chief Financial Officer and Sr. VP', 'pay': '947.22k', 'exercised': '147.98k', 'age': '45'}","{'name': 'Mr. John  Nicholson', 'title': 'Chief Operating Officer and Sr. VP', 'pay': '982.03k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. Stephen K. Doberstein Ph.D.', 'title': 'Sr. VP of R&D and Chief R&D Officer', 'pay': '787.81k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Maninder  Hora Ph.D.', 'title': 'Sr. VP of Pharmaceutical Devel. and Manufacturing Operations', 'pay': '742.13k', 'exercised': 'N/A', 'age': '63'}"
NLNK,NewLink Genetics Corporation,http://www.newlinkgenetics.com,Healthcare,Biotechnology,122,"NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The companys HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.","{'name': 'Mr. Charles J. Link Jr., M.D.', 'title': 'Co-Founder, Chairman, CEO & Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Nicholas N. Vahanian M.D.', 'title': 'Co-Founder, Pres, Chief Medical Officer & Director (leave of absence)', 'pay': '805.08k', 'exercised': '3.56M', 'age': '51'}","{'name': 'Mr. John B. Henneman III', 'title': 'Exec. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Brian  Wiley', 'title': 'Chief Commercial Officer', 'pay': '477.85k', 'exercised': '1.58M', 'age': '50'}","{'name': 'Mr. Carl W. Langren', 'title': 'VP of Fin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '63'}"
NSTG,"NanoString Technologies, Inc.",http://www.nanostring.com,N/A,N/A,N/A,"NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.","{'name': 'Mr. R. Bradley  Gray', 'title': 'Pres, CEO & Director', 'pay': '912.57k', 'exercised': 'N/A', 'age': '41'}","{'name': 'Mr. James A. Johnson', 'title': 'Chief Financial Officer', 'pay': '538.25k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. David W. Ghesquiere', 'title': 'Sr. VP of Corp. & Bus. Devel.', 'pay': '508.85k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Mary Tedd Allen Ph.D.', 'title': 'Sr. VP of Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Douglas S. Farrell', 'title': 'VP of Investor Relations & Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
NTLA,Intellia Therapeutics Inc.,http://www.intelliatx.com,N/A,N/A,N/A,"Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Nessan  Bermingham Ph.D.', 'title': 'Founder, CEO, Pres, Director & Member of Scientific Advisor Board', 'pay': '675.72k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Ms. Rachel  Haurwitz  Ph.D.', 'title': 'Co-Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': '32'}","{'name': 'Mr. Jos?? E. Rivera J.D., Esq.', 'title': 'Exec. VP of Operations and Gen. Counsel', 'pay': '564.39k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. John M. Leonard M.D.', 'title': 'Exec. VP of R & D and Director', 'pay': '464.73k', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Andrew  May Ph.D.', 'title': 'Founder and Member of Scientific Advisor Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
NVAX,"Novavax, Inc.",http://www.novavax.com,Healthcare,Biotechnology,348,"Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.","{'name': 'Mr. Stanley Charles Erck', 'title': 'CEO, Pres, Interim CFO & Director', 'pay': '625.38k', 'exercised': '1.56M', 'age': '69'}","{'name': 'Mr. John A. Herrmann III, J.D.', 'title': 'Sr. VP, Gen. Counsel & Corp. Sec.', 'pay': '342.5k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. John Joseph Trizzino B.S., M.B.A.', 'title': 'Sr. VP of Commercial Operations', 'pay': '366.89k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Gregory M. Glenn M.D.', 'title': 'Pres of R&D', 'pay': '448.75k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Barclay A. Phillips', 'title': 'Consultant', 'pay': '370.75k', 'exercised': 'N/A', 'age': '54'}"
NVCR,NovoCure Limited,http://www.novocure.com,N/A,N/A,N/A,"NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.","{'name': 'Mr. William F. Doyle', 'title': 'Exec. Chairman', 'pay': '596.96k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Asaf  Danziger', 'title': 'CEO & Director', 'pay': '927.75k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Kinyip Gabriel Leung', 'title': 'Vice Chairman and Chairman of The Global Commercialization Team', 'pay': '162k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Prof. Yoram  Palti M.D., Ph.D.', 'title': 'Founder, Chief Technology Officer and Director', 'pay': '280.98k', 'exercised': 'N/A', 'age': '80'}","{'name': 'Mr. Wilhelmus C. M. Groenhuysen', 'title': 'Chief Financial Officer', 'pay': '629.07k', 'exercised': 'N/A', 'age': '60'}"
OMER,Omeros Corporation,http://www.omeros.com,Healthcare,Biotechnology,154,"Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The companys clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The companys preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.","{'name': 'Dr. Gregory A. Demopulos M.D.', 'title': 'Co-Founder, Chairman, Chief Exec. Officer and Pres', 'pay': '1.04M', 'exercised': '8.92M', 'age': '59'}","{'name': 'Mr. Michael A. Jacobsen', 'title': 'Chief Accounting Officer, VP of Fin. and Treasurer', 'pay': '391.23k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Ms. Marcia S. Kelbon Esq., J.D., M.S.', 'title': 'VP of Patent, Gen. Counsel and Sec.', 'pay': '467.09k', 'exercised': '1.92M', 'age': '58'}","{'name': 'Dr. Pamela Pierce Palmer M.D., Ph.D.', 'title': 'Co-Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. George A. Gaitanaris M.D., Ph.D.', 'title': 'Chief Scientific Officer and VP of Science', 'pay': 'N/A', 'exercised': 'N/A', 'age': '61'}"
ONCE,"Spark Therapeutics, Inc.",http://www.sparktx.com,N/A,N/A,N/A,"Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The companys products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease and Huntington's disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of rare genetic blinding conditions, hematologic disorders, and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.","{'name': 'Mr. Jeffrey D. Marrazzo M.B.A., M.P.A.', 'title': 'Co-Founder, CEO & Director', 'pay': '999.79k', 'exercised': '4.95M', 'age': '39'}","{'name': 'Dr. Katherine A. High M.D.', 'title': 'Co-Founder, Pres, Head of R&D and Director', 'pay': '704.53k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Mr. Stephen W. Webster', 'title': 'Chief Financial Officer', 'pay': '654.99k', 'exercised': '938.8k', 'age': '57'}","{'name': 'Mr. John  Furey', 'title': 'Chief Operating Officer', 'pay': '40.59k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Daniel R. Faga', 'title': 'Chief Bus. Officer', 'pay': '590.29k', 'exercised': 'N/A', 'age': '38'}"
OPK,"Opko Health, Inc.",http://www.opko.com,Healthcare,Biotechnology,"6,041","OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.","{'name': 'Phillip  Frost', 'title': 'Chairman and Chief Exec. Officer', 'pay': '970.6k', 'exercised': 'N/A', 'age': '81'}","{'name': 'Dr. Jane H. Hsiao Ph.D., MBA', 'title': 'Vice Chairman and Chief Technical Officer', 'pay': '970.6k', 'exercised': 'N/A', 'age': '70'}","{'name': 'Mr. Adam E. Logal', 'title': 'Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer', 'pay': '610.6k', 'exercised': 'N/A', 'age': '39'}","{'name': 'Mr. Steven D. Rubin', 'title': 'Exec. VP of Admin. and Director', 'pay': '820.6k', 'exercised': '2.29M', 'age': '57'}","{'name': 'Ms. Kate  Inman Esq.', 'title': 'Deputy Gen. Counsel and Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}"
PACB,"Pacific Biosciences of California, Inc.",http://www.pacb.com,Healthcare,Biotechnology,438,"Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The companys single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distributors in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.","{'name': 'Dr. Michael W. Hunkapiller Ph.D.', 'title': 'Exec. Chairman, Chief Exec. Officer and Pres', 'pay': '1', 'exercised': 'N/A', 'age': '68'}","{'name': 'Ms. Susan K. Barnes', 'title': 'Chief Financial Officer, Principal Accounting Officer and Exec. VP', 'pay': '1', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. James Michael Phillips', 'title': 'Sr. VP of R&D', 'pay': '393.22k', 'exercised': '420.81k', 'age': '66'}","{'name': 'Mr. Kevin P. Corcoran', 'title': 'Sr. VP of Market Devel.', 'pay': '393.22k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Ms. Kathy P. Ordo??ez', 'title': 'Chief Commercial Officer, Exec. VP & Director', 'pay': '52k', 'exercised': 'N/A', 'age': '66'}"
PBYI,"Puma Biotechnology, Inc.",http://www.pumabiotechnology.com,N/A,N/A,N/A,"Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.","{'name': 'Mr. Alan H. Auerbach', 'title': 'Founder, Chairman, Chief Exec. Officer, Pres and Sec.', 'pay': '1.26M', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Charles R. Eyler', 'title': 'Sr. VP of Fin. & Admin. and Treasurer', 'pay': '605.52k', 'exercised': 'N/A', 'age': '70'}","{'name': 'Dr. Richard P. Bryce MBChB, MRCGP, MFPM', 'title': 'Chief Medical & Scientific Officer', 'pay': '634.62k', 'exercised': '158.54k', 'age': '61'}","{'name': 'Mr. Steven  Lo', 'title': 'Chief Commercial Officer', 'pay': '719.97k', 'exercised': 'N/A', 'age': '51'}",
PCRX,"Pacira Pharmaceuticals, Inc.",http://www.pacira.com,N/A,N/A,N/A,"Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The companys lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its development pipeline comprises DepoTranexamic Acid, a long-acting local antifibrinolytic agent, which is in Phase II clinical development for the treatment or prevention of excessive blood loss during surgery by preventing the breakdown of a clot; and DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.","{'name': 'Mr. David M. Stack', 'title': 'Chairman and Chief Exec. Officer', 'pay': '1.17M', 'exercised': '4.52M', 'age': '68'}","{'name': 'Mr. Charles A. Reinhart III', 'title': 'Chief Financial Officer', 'pay': '386.83k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Scott  Braunstein M.D.', 'title': 'Chief Operating Officer', 'pay': '554.4k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Ms. Kristen  Williams J.D.', 'title': 'Chief Admin. Officer, Gen. Counsel and Sec.', 'pay': '552.13k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Ms. Lauren Bullaro Riker', 'title': 'Principal Accounting Officer & VP of Fin.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '39'}"
PDLI,"PDL BioPharma, Inc.",http://www.pdl.com,Healthcare,Biotechnology,10,"PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.","{'name': 'Mr. John Peter McLaughlin J.D.', 'title': 'CEO & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. Peter S. Garcia', 'title': 'VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Steffen  Pietzke CPA', 'title': 'VP of Fin. & Chief Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Christopher L. Stone J.D.', 'title': 'VP, Gen. Counsel & Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Dominique P. Monnet', 'title': 'Pres', 'pay': 'N/A', 'exercised': 'N/A', 'age': '56'}"
PETQ,"PetIQ, Inc.",http://www.petiq.com,N/A,N/A,N/A,"PetIQ, Inc. develops, manufactures, and sells pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements. The company provides its products under the PetIQ, PetAction, Advecta, PetLock, Heart Shield, TruProfen, Betsy Farms, Minties, Vera, Delightibles, vetGuard, Mimis Market, PAWS IQ, VET + CHOICE, VET WORKS, TEX RANCH and VetIQ brands. It is also involved in the wholesale distribution of over-the-counter and prescription pet medications, and pet wellness products. The company sells its products through distributors as well as through retail stores in mass, club, grocery, pharmacy, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho. PetIQ, Inc. is a subsidiary of PetIQ Holdings LLC.","{'name': 'Mr. Mccord  Christensen', 'title': 'Chairman of Directors & CEO', 'pay': '421k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. John  Newland', 'title': 'CFO & Corp. Sec.', 'pay': '416k', 'exercised': 'N/A', 'age': '54'}",,,
PETX,"Aratana Therapeutics, Inc.",http://www.aratana.com,N/A,N/A,N/A,"Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companys licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.","{'name': 'Dr. Steven  St. Peter M.D.', 'title': 'Co-Founder, Chief Exec. Officer, Pres & Director', 'pay': '697.8k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Craig A. Tooman MBA', 'title': 'CFO & Treasurer', 'pay': '475.4k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Brent A. Standridge', 'title': 'Chief Operating Officer', 'pay': '339.4k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. Ernst  Heinen D.V.M., Ph.D.', 'title': 'Chief Devel. Officer', 'pay': '402.3k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. John C. Ayres J.D.', 'title': 'Gen. Counsel & Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
PGNX,"Progenics Pharmaceuticals, Inc.",http://www.progenics.com,N/A,N/A,N/A,"Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The companys primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient, as well as for treatment of OIC in patients with non-cancer pain; and Relistor-oral tablets for the treatment of OIC. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York, New York.","{'name': 'Mr. Mark R. Baker J.D.', 'title': 'Chief Exec. Officer and Director', 'pay': '962.64k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Patrick  Fabbio', 'title': 'Chief Financial Officer and Sr. VP', 'pay': '509.07k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Vivien  Wong Ph.D.', 'title': 'Exec. VP of Devel.', 'pay': '555.13k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Jeffrey D. Summer', 'title': 'Sr. VP of Digital Technology', 'pay': '305.22k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Bryce V. Tenbarge', 'title': 'VP of Commercial', 'pay': '171.84k', 'exercised': 'N/A', 'age': '44'}"
PRAH,"PRA Health Sciences, Inc.",http://www.prahs.com,N/A,N/A,N/A,"PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. The companys services also comprise strategic solutions comprising embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services consisting of Phase I through Phase IIa studies and bioanalytical laboratory services. It conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. The company was founded in 1976 and is headquartered in Raleigh, North Carolina.","{'name': 'Mr. Colin  Shannon', 'title': 'Chairman, CEO & Pres', 'pay': '1.13M', 'exercised': '9.05M', 'age': '59'}","{'name': 'Ms. Linda  Baddour', 'title': 'Exec. VP, CFO & Corp. Sec.', 'pay': '601.7k', 'exercised': '11.35M', 'age': '60'}","{'name': 'Dr. David W. Dockhorn Ph.D.', 'title': 'Exec. VP & Compliance Officer', 'pay': '496.28k', 'exercised': '5.27M', 'age': '57'}","{'name': 'Michael J. Bonello', 'title': 'Sr. VP of Accounting and Corp. Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Christine  Rogers', 'title': 'Director of PR & Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
PRTA,Prothena Corporation plc,http://www.prothena.com,N/A,N/A,N/A,"Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinsons disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dún Laoghaire, Ireland.","{'name': 'Mr. Gene G. Kinney Ph.D.', 'title': 'Pres, CEO & Director', 'pay': '645.61k', 'exercised': '1.43M', 'age': '49'}","{'name': 'Mr. Tran B. Nguyen M.B.A.', 'title': 'Chief Financial Officer', 'pay': '532.64k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Mr. Arthur W. Homan J.D.', 'title': 'Chief Legal Officer', 'pay': '492.24k', 'exercised': '614.19k', 'age': '59'}","{'name': 'Ms. Carol D. Karp', 'title': 'Chief Regulatory Officer', 'pay': '324.49k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Ms. Karin L. Walker CPA', 'title': 'Chief Accounting Officer & Controller', 'pay': 'N/A', 'exercised': 'N/A', 'age': '55'}"
PRTK,"Paratek Pharmaceuticals, Inc.",http://paratekpharma.com,N/A,N/A,N/A,"Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.","{'name': 'Mr. Michael F. Bigham CPA, MBA', 'title': 'Chairman and Chief Exec. Officer', 'pay': '663.43k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Evan  Loh M.D., FACC, FAHA', 'title': 'Pres, Chief Medical Officer, COO & Director', 'pay': '620.78k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Douglas W. Pag??n', 'title': 'Chief Financial Officer', 'pay': '457.82k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. William M. Haskel', 'title': 'Sr. VP, Gen. Counsel and Corp. Sec.', 'pay': '569.77k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Adam  Woodrow', 'title': 'Chief Commercial Officer and VP', 'pay': '466.27k', 'exercised': 'N/A', 'age': '50'}"
PTCT,"PTC Therapeutics, Inc.",http://www.ptcbio.com,Healthcare,Biotechnology,298,"PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companys product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.","{'name': 'Dr. Stuart  W. Peltz Ph.D.', 'title': 'Co-Founder, Chief Exec. Officer and Exec. Director', 'pay': '887.6k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Dr. Allan Steven Jacobson Ph.D.', 'title': 'Co-Founder, Chairman of Scientific Advisory Board and Director', 'pay': '135k', 'exercised': 'N/A', 'age': '71'}","{'name': 'Dr. Neil  Almstead Ph.D.', 'title': 'Exec. VP of Research, Pharmaceutical Operations & Technology', 'pay': '574.45k', 'exercised': '10.3k', 'age': '50'}","{'name': 'Mr. Mark Elliott Boulding', 'title': 'Chief Legal Officer, EVP & Sec.', 'pay': '579.23k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Cameron  Geoffrey  McDonough M.D.', 'title': 'Advisor', 'pay': '45k', 'exercised': 'N/A', 'age': '47'}"
PTLA,"Portola Pharmaceuticals, Inc.",http://www.portola.com,Healthcare,Biotechnology,163,"Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.","{'name': 'Mr. William  Lis', 'title': 'CEO, Pres & Director', 'pay': '740.85k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Ms. Mardi C. Dier', 'title': 'CFO & Exec. VP', 'pay': '603.43k', 'exercised': '354.25k', 'age': '54'}","{'name': 'Dr. John T. Curnutte M.D., Ph.D.', 'title': 'Exec. VP of R&D', 'pay': '575.19k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Mr. Tao  Fu', 'title': 'Chief Commercial & Bus. Officer and Exec. VP', 'pay': '580.72k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Jeet  Mahal', 'title': 'VP of Bus. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
QGEN,QIAGEN N.V.,http://www.qiagen.com,Services,Research Services,"4,600","QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. The company provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. It also offers instrumentation systems for laboratories. The companys automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories; Modaplex, a multimodal automation system; QIAcube, a sample processing instrument; EZ1 Advanced XL for automated nucleic acid purification; QIAxcel for nucleic acid separation; QIAscout that enables researchers to select and isolate viable single cells; PyroMark, a detection platform that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns; QIAgility, a benchtop instrument; and ESEQuant instruments that enable optical measurement for point of need molecular testing in healthcare and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a partnership with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.","{'name': 'Mr. Peer Michael Schatz', 'title': 'CEO, MD & Member of Management Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Roland  Sackers', 'title': 'CFO, MD & Member of Management Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Mark  Gladwell', 'title': 'Sr. VP of Global Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '42'}","{'name': 'Mr. John  Gilardi', 'title': 'VP of Corp. Communications & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Jean-Pascal  Viola', 'title': 'Head of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VP', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
QURE,uniQure N.V.,http://www.uniqure.com,Healthcare,Biotechnology,251,"uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companys principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","{'name': 'Mr. Matthew Craig Kapusta', 'title': 'CEO, Interim CFO & Exec. Director', 'pay': '551.55k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Dr. Sander  van Deventer M.D., Ph.D.', 'title': 'Co-Founder, Chief Scientific Officer & GM of Amsterdam', 'pay': '45k', 'exercised': 'N/A', 'age': '63'}","{'name': 'Prof. Hugo  Katus', 'title': 'Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Scott T. McMillan Ph.D.', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Christian  Klemt', 'title': 'Chief Accounting Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '44'}"
RARE,Ultragenyx Pharmaceutical Inc.,http://www.ultragenyx.com,Healthcare,Biotechnology,376,"Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude Childrens Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.","{'name': 'Dr. Emil D. Kakkis M.D., Ph.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '945.9k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Ms. Shalini  Sharp', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '658.44k', 'exercised': '2.9M', 'age': '42'}","{'name': 'Ms. Karah Herdman Parschauer', 'title': 'Exec. VP and Gen. Counsel', 'pay': '320.96k', 'exercised': 'N/A', 'age': '39'}","{'name': 'Mr. John Richard Pinion II', 'title': 'Chief Quality Operations Officer and Exec. VP of Analytical Sciences & Research', 'pay': '601.46k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Jayson Donald Alexander Dallas M.D.', 'title': 'Chief Commercial Officer and Exec. VP', 'pay': '697.26k', 'exercised': 'N/A', 'age': '49'}"
RARX,"Ra Pharmaceuticals, Inc.",http://www.rapharma.com,,,46,"Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companys peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companys preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.","{'name': 'Dr. Douglas A. Treco Ph.D.', 'title': 'Chief Exec. Officer, Pres, Co-Founder and Director', 'pay': '590.43k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. David C. Lubner CPA', 'title': 'Chief Financial Officer and Exec. VP of Operations', 'pay': '500.44k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Simon  Read Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '337.81k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Ramin  Farzaneh-Far M.D., FACC', 'title': 'Chief Medical Officer', 'pay': '407.21k', 'exercised': 'N/A', 'age': '40'}","{'name': 'Ms. Kerry  Black M.S., M.B.A.', 'title': 'Exec. Director of Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
RDUS,"Radius Health, Inc.",http://www.radiuspharm.com,Healthcare,Biotechnology,170,"Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.","{'name': 'Dr. Gregory  Williams Ph.D., MBA', 'title': 'Chief Devel. Officer', 'pay': '563.9k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Lorraine A. Fitzpatrick M.D.', 'title': 'Chief Medical Officer', 'pay': '543.79k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Mr. Brian Nicholas Harvey', 'title': 'Advisor', 'pay': '478.84k', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. Jesper  H??iland M.Sc.', 'title': 'CEO & Pres', 'pay': 'N/A', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Stavros C. Manolagas M.D., Ph.D.', 'title': 'Co-Founder and Member of the Scientific Advisory Board', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
REGN,"Regeneron Pharmaceuticals, Inc.",http://www.regeneron.com,Healthcare,Biotechnology,"5,653","Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.","{'name': 'Dr. Leonard S. Schleifer M.D., Ph.D.', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Exec. Director', 'pay': '3.71M', 'exercised': '89.94M', 'age': '64'}","{'name': 'Dr. George D. Yancopoulos M.D., Ph.D.', 'title': 'Pres, Chief Scientific Officer and Director', 'pay': '3.14M', 'exercised': '70.18M', 'age': '57'}","{'name': 'Mr. Robert E. Landry Jr.', 'title': 'Chief Financial Officer and Sr. VP of Fin.', 'pay': '1.21M', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Neil  Stahl Ph.D.', 'title': 'Exec. VP of R&D', 'pay': '1.2M', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Robert J. Terifay', 'title': 'Exec. VP of Commercial', 'pay': '1.07M', 'exercised': 'N/A', 'age': '57'}"
RETA,"Reata Pharmaceuticals, Inc.",http://www.reatapharma.com,N/A,N/A,N/A,"Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of Friedreichs ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.","{'name': 'Mr. J. Warren Huff', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '756k', 'exercised': 'N/A', 'age': '64'}","{'name': 'Dr. Colin J. Meyer M.D.', 'title': 'Chief Medical Officer and VP of Product Devel.', 'pay': '487.5k', 'exercised': 'N/A', 'age': '39'}","{'name': 'Dr. Keith W. Ward Ph.D.', 'title': 'Chief Devel. Officer and VP', 'pay': '450k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Jason D. Wilson', 'title': 'Chief Financial Officer and VP of Strategy', 'pay': 'N/A', 'exercised': 'N/A', 'age': '48'}","{'name': 'Ms. Elaine  Castellanos', 'title': 'VP of Fin. and Accounting', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
RGEN,Repligen Corporation,http://www.repligen.com,N/A,N/A,N/A,"Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody-based therapeutics, recombinant proteins, and vaccines worldwide. It manufactures various forms of Protein A, a critical component used to purify antibody-based drugs. The company also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields. In addition, it manufactures and sells OPUS pre-packed chromatography columns, which are used in the purification of clinical-stage biologics; and tangential flow filtration cassettes that are used to concentrate clinical and commercial stage biologic drugs. Further, the company has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreichs ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical companies, and contract manufacturers. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.","{'name': 'Mr. Anthony J. Hunt', 'title': 'Chief Exec. Officer, Pres, Director and Member of Scientific Advisory Board', 'pay': '903.25k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. Jon K. Snodgres', 'title': 'Chief Financial Officer and Sec.', 'pay': '523.35k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Howard  Benjamin Ph.D.', 'title': 'VP of Bus. Devel.', 'pay': '411.99k', 'exercised': '177.49k', 'age': '57'}","{'name': 'Mr. Steve  Curran', 'title': 'VP of Global Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Sondra S. Newman', 'title': 'Sr. Director Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
RGNX,Regenxbio Inc.,http://www.regenxbio.com,N/A,N/A,N/A,"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The companys lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV vectors to various other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.","{'name': 'Mr. Kenneth T. Mills', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '720.89k', 'exercised': '1.29M', 'age': '42'}","{'name': 'Mr. Curran M. Simpson', 'title': 'Sr. VP of Technical Operations', 'pay': '457.11k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mr. Faraz  Ali', 'title': 'Chief Bus. Officer', 'pay': '397.5k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Dr. James M. Wilson M.D., Ph.D.', 'title': 'Scientific Founder and Special Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Vittal K. Vasista', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}"
RIGL,"Rigel Pharmaceuticals, Inc.",http://www.rigel.com,Healthcare,Drugs - Generic,77,"Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companys clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.","{'name': 'Mr. Raul R. Rodriguez', 'title': 'CEO, Pres & Director', 'pay': '862.37k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Ryan D. Maynard', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '603.5k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Ms. Dolly A. Vance', 'title': 'Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.', 'pay': '650.8k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Dr. Anne-Marie S. Duliege M.D., M.S.', 'title': 'Chief Medical Officer and Exec. VP', 'pay': '541.2k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Eldon C. Mayer III', 'title': 'Chief Commercial Officer and Exec. VP', 'pay': '175.92k', 'exercised': 'N/A', 'age': '56'}"
RTRX,"Retrophin, Inc.",http://www.retrophin.com,N/A,N/A,N/A,"Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The companys product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.","{'name': 'Mr. Stephen J. Aselage', 'title': 'CEO, Pres & Director', 'pay': '781.78k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Ms. Laura M. Clague CPA', 'title': 'CFO & Sr. VP', 'pay': '533.12k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Neil F. McFarlane', 'title': 'Chief Operating Officer', 'pay': '367.13k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Chris  Cline CFA', 'title': 'VP of Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Ms. Elizabeth E. Reed J.D.', 'title': 'Sr. VP, Gen. Counsel & Corp. Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '47'}"
RVNC,"Revance Therapeutics, Inc.",http://www.revance.com,Healthcare,Biotechnology,131,"Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.","{'name': 'Mr. L. Daniel Browne', 'title': 'Co-Founder, CEO, Pres & Director', 'pay': '783.49k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Mrs. Lauren P. Silvernail', 'title': 'Chief Financial Officer, Chief Bus. Officer and Sec.', 'pay': '651.86k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Abhay  Joshi Ph.D., M.B.A.', 'title': 'Chief Operating Officer', 'pay': '800.88k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Justin  Ford', 'title': 'Head of People & VP of HR', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Todd Erik Zavodnick', 'title': 'Chief Commercial Officer and Pres of Aesthetics & Therapeutics', 'pay': 'N/A', 'exercised': 'N/A', 'age': '45'}"
SAGE,"Sage Therapeutics, Inc.",http://www.sagerx.com,Healthcare,Biotechnology,135,"Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companys product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinsons diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.","{'name': 'Dr. Jeffrey M. Jonas M.D.', 'title': 'CEO, Pres & Director', 'pay': '813.02k', 'exercised': '918.8k', 'age': '64'}","{'name': 'Ms. Kimi E. Iguchi CPA', 'title': 'CFO & Treasurer', 'pay': '480.79k', 'exercised': '183.76k', 'age': '55'}","{'name': 'Dr. Albert J. Robichaud Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '541.52k', 'exercised': '642', 'age': '56'}","{'name': 'Ms. Anne Marie Cook Esq.', 'title': 'Sr. VP, Gen. Counsel & Sec.', 'pay': '538.72k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Stephen J. Kanes M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '574.58k', 'exercised': '783.72k', 'age': '52'}"
SBBP,Strongbridge Biopharma plc,http://www.strongbridgebio.com,N/A,N/A,N/A,"Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous Cushings syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.","{'name': 'Mr. Matthew  Pauls', 'title': 'Pres, CEO & Director', 'pay': '666.9k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. A. Brian Davis', 'title': 'Chief Financial Officer', 'pay': '458.61k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Fredric  Cohen M.D.', 'title': 'Chief Medical Officer', 'pay': '453.65k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Per  Marin M.D., Ph.D.', 'title': 'Founder and Sr. Clinical Advisor', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Peter J. Valentinsson', 'title': 'Sr. VP of Global Technical Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
SCMP,"Sucampo Pharmaceuticals, Inc.",http://www.sucampo.com,N/A,N/A,N/A,"Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The companys marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.","{'name': 'Mr. Peter S. Greenleaf', 'title': 'Chairman & CEO', 'pay': '1.28M', 'exercised': '2.02M', 'age': '47'}","{'name': 'Dr. Peter A. Kiener Ph.D.', 'title': 'Chief Science Officer', 'pay': '699.67k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Mr. Matthew Maxwell Donley', 'title': 'Exec. VP of Global HR, Information Technology and Strategy', 'pay': '668.63k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Peter P. Pfreundschuh CPA', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '48'}","{'name': 'Ms. Silvia  Taylor MBA', 'title': 'Sr. VP of Investor Relations and Corp. Affairs', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
SGEN,"Seattle Genetics, Inc.",http://www.seattlegenetics.com,Healthcare,Biotechnology,890,"Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.","{'name': 'Dr. Clay B. Siegall Ph.D.', 'title': 'Co-Founder, Pres, CEO & Chairman', 'pay': '1.86M', 'exercised': '8.7M', 'age': '56'}","{'name': 'Mr. Todd E. Simpson', 'title': 'Chief Financial Officer', 'pay': '757.28k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Eric L. Dobmeier J.D.', 'title': 'Chief Operating Officer', 'pay': '727.84k', 'exercised': '1.63M', 'age': '48'}","{'name': 'Dr. Vaughn B. Himes Ph.D.', 'title': 'Chief Technology Officer', 'pay': '700.44k', 'exercised': '2.41M', 'age': '56'}","{'name': 'Dr. Jonathan G. Drachman M.D.', 'title': 'Chief Medical Officer and Exec. VP of R&D', 'pay': '817.17k', 'exercised': '720.86k', 'age': '55'}"
SGMO,"Sangamo Therapeutics, Inc.",http://www.sangamo.com,Healthcare,Biotechnology,131,"Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companys proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntingtons disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.","{'name': 'Dr. Alexander D. Macrae M.B., Ch.B, Ph.D., MRCP', 'title': 'Pres, CEO & Director', 'pay': '697k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Curt A. Herberts III', 'title': 'Sr. VP & Chief Bus. Officer', 'pay': '362.26k', 'exercised': 'N/A', 'age': '36'}","{'name': 'Dr. Edward R. Conner M.D.', 'title': 'Sr. VP & Chief Medical Officer', 'pay': '134.85k', 'exercised': 'N/A', 'age': '44'}","{'name': 'Ms. Kathy Y. Yi', 'title': 'Sr. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '45'}","{'name': 'Dr. R. Andrew Ramelmeier Ph.D.', 'title': 'Sr. VP of Technical Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
SGYP,Synergy Pharmaceuticals Inc.,http://www.synergypharma.com,N/A,N/A,N/A,"Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.","{'name': 'Dr. Gary S. Jacob Ph.D.', 'title': 'Chairman, CEO & Pres', 'pay': '844.01k', 'exercised': 'N/A', 'age': '70'}","{'name': 'Dr. Kunwar  Shailubhai Ph.D., M.B.A.', 'title': 'Chief Scientific Officer and Exec. VP', 'pay': '524.29k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Patrick H. Griffin M.D., FACP', 'title': 'Exec. VP & Chief Medical Officer', 'pay': '607.65k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Mr. Troy  Hamilton Pharm.D.', 'title': 'Exec. VP & Chief Commercial Officer', 'pay': '567.5k', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. Gary G. Gemignani', 'title': 'Exec. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '52'}"
SHPG,Shire plc,http://www.shire.com,N/A,N/A,N/A,"Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; and SFJ Pharmaceuticals Group. Shire plc was founded in 1986 and is based in Dublin, Ireland.","{'name': 'Dr. Flemming  Ornskov M.D., MBA, MPH', 'title': 'CEO, MD & Exec. Director', 'pay': '5.43M', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Jeffrey   Poulton', 'title': 'CFO & Exec. Director', 'pay': '1.62M', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Matthew  Walker BSCHE', 'title': 'Head of Technical Operations', 'pay': 'N/A', 'exercised': 'N/A', 'age': '53'}","{'name': 'Mr. William Richard Mordan', 'title': 'Gen. Counsel & Corp. Sec.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mrs. Jessica  Mann', 'title': 'Sr. VP of Global Corp. Communications', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
SNDX,"Syndax Pharmaceuticals, Inc.",http://www.syndax.com,N/A,N/A,N/A,"Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The companys lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, and Merck KGaA and Pfizer; collaborative research and development agreement with National Cancer Institute; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.","{'name': 'Dr. Briggs W. Morrison M.D.', 'title': 'Chief Exec. Officer and Director', 'pay': '872.68k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Michael A. Metzger M.B.A.', 'title': 'Pres and Chief Operating Officer', 'pay': '731.86k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. Richard P. Shea', 'title': 'Chief Financial Officer, Principal Accounting Officer and Treasurer', 'pay': '39k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Dr. Michael L. Meyers M.D., Ph.D.', 'title': 'Chief Medical Officer and Sr. VP', 'pay': '550.81k', 'exercised': 'N/A', 'age': '67'}","{'name': 'Dr. Peter  Ordentlich Ph.D.', 'title': 'Co-Founder and Chief Scientific Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}"
SNNA,"Sienna Biopharmaceuticals, Inc.",http://www.siennabio.com.,N/A,N/A,N/A,"Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The companys lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.","{'name': 'Dr. Frederick C. Beddingfield III, M.D., Ph.D.', 'title': 'Pres, CEO & Director', 'pay': '485.96k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Todd  Harris Ph.D.', 'title': 'Head of Corp. Devel. & Director', 'pay': '448.8k', 'exercised': 'N/A', 'age': '39'}","{'name': 'Dr. Paul F. Lizzul M.D., Ph.D., M.P.H., M.B.A., FAAD', 'title': 'Chief Medical Officer', 'pay': '311.61k', 'exercised': 'N/A', 'age': '43'}","{'name': 'Ms. Diane  Stroehmann M.S., R.A.C.', 'title': 'Chief of Staff and Head of Regulatory Affairs & Quality', 'pay': '308.85k', 'exercised': 'N/A', 'age': '41'}","{'name': 'Mr. Richard D. Peterson', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}"
SPPI,"Spectrum Pharmaceuticals, Inc.",http://www.sppirx.com,N/A,N/A,N/A,"Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.","{'name': 'Mr. Joseph W. Turgeon', 'title': 'Pres , CEO & Director', 'pay': '1.03M', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Kurt A. Gustafson', 'title': 'Chief Financial Officer, Principal Accounting Officer and Exec. VP', 'pay': '857.16k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Thomas J. Riga', 'title': 'Chief Operating Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Shiv  Kapoor', 'title': 'VP of Strategic Planning & Investor Relations', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Bimal R. Shah', 'title': 'VP of Corp. and Bus. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
SRPT,"Sarepta Therapeutics, Inc.",http://www.sarepta.com,N/A,N/A,N/A,"Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charleys Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Sandesh  Mahatme LL.M.', 'title': 'Exec. VP, CFO & Chief Bus. Officer', 'pay': '704.13k', 'exercised': '81.21k', 'age': '53'}","{'name': 'Mr. David Tyronne Howton Jr.', 'title': 'Sr. VP, Gen. Counsel & Corp. Sec.', 'pay': '615.34k', 'exercised': '72k', 'age': '46'}","{'name': 'Mr. Alexander Bo Cumbo', 'title': 'Sr. VP & Chief Commercial Officer', 'pay': '478.15k', 'exercised': '39.34k', 'age': '47'}","{'name': 'Ms. Shamim  Ruff', 'title': 'Sr. VP of Regulatory Affairs & Quality', 'pay': '542.55k', 'exercised': '47.21k', 'age': '58'}","{'name': 'Dr. Edward M. Kaye M.D., Ph.D.', 'title': 'Advisor', 'pay': '979.3k', 'exercised': '1.09M', 'age': '69'}"
SUPN,"Supernus Pharmaceuticals, Inc.",,Healthcare,Drugs - Generic,363,"Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The companys product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.","{'name': 'Mr. Jack A. Khattar', 'title': 'Founder, Chief Exec. Officer, Pres, Sec. and Director', 'pay': '1.13M', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Gregory S. Patrick M.E., M.B.A.', 'title': 'Chief Financial Officer and VP', 'pay': '504.75k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Dr. Padmanabh P. Bhatt Ph.D.', 'title': 'Chief Scientific Officer and Sr. VP of Intellectual Property', 'pay': '502.75k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Victor L. Vaughn', 'title': 'Sr. VP of Sales and Marketing', 'pay': '517.16k', 'exercised': 'N/A', 'age': '59'}","{'name': 'Dr. Stefan K. F. Schwabe M.D., Ph.D.', 'title': 'Chief Medical Officer and Exec. VP of R&D', 'pay': '566.66k', 'exercised': 'N/A', 'age': '65'}"
SVRA,Savara Inc.,http://savarapharma.com,N/A,N/A,N/A,"Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. The company is headquartered in Austin, Texas.","{'name': 'Mr. Robert  Neville', 'title': 'Co-Founder, Exec. Chairman & CEO', 'pay': '340.5k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. Jaakko  Taneli Jouhikainen M.D., Ph.D., MBA', 'title': 'Pres & COO', 'pay': '352.5k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. David L. Lowrance CPA', 'title': 'Chief Financial Officer', 'pay': '50.42k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Joseph F. Bossart B.Sc. Ph.D.', 'title': 'VP of Bus. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. John  Lord Ph.D.', 'title': 'Head of Pharmaceutical Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
TBPH,"Theravance Biopharma, Inc.",http://www.theravance.com,N/A,N/A,N/A,"Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companys product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.","{'name': 'Mr. Rick E. Winningham', 'title': 'Chairman & CEO', 'pay': '1.53M', 'exercised': 'N/A', 'age': '58'}","{'name': 'Ms. Ren??e D. Gal??', 'title': 'CFO, Sr. VP & Treasurer', 'pay': '681.5k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. Bradford J. Shafer', 'title': 'Exec. VP, Gen. Counsel & Sec.', 'pay': '762.29k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Dr. Sharathchandra S. Hegde Ph.D.', 'title': 'Sr. VP of Research', 'pay': '617.51k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Dr. Phillip D. Worboys Ph.D.', 'title': 'Sr. VP of Translational Science', 'pay': '618.82k', 'exercised': 'N/A', 'age': '48'}"
TECH,Bio-Techne Corporation,http://www.bio-techne.com,Healthcare,Biotechnology,"1,789","Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.","{'name': 'Mr. Charles R. Kummeth', 'title': 'Pres, CEO & Director', 'pay': '2.06M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. James T. Hippel', 'title': 'Sr. VP of Fin., CFO & Principal Accounting Officer', 'pay': '855.7k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Mr. N. David Eansor', 'title': 'Sr. VP of Biotechnology Division', 'pay': '690.06k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Mr. Robert M. Gavin', 'title': 'Sr. VP of Protein Platforms Division', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Kevin S. Gould', 'title': 'Sr. VP of Diagnostics Division', 'pay': '425.26k', 'exercised': 'N/A', 'age': '51'}"
TLGT,"Teligent, Inc.",http://www.teligent.com,,,112,"Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The companys products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.","{'name': 'Mr. Jason  Grenfell-Gardner M.B.A', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '732.6k', 'exercised': 'N/A', 'age': '43'}","{'name': 'Mrs. Jenniffer L. Collins', 'title': 'Chief Financial Officer and Sec.', 'pay': '368.77k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Mr. Stephen  Richardson', 'title': 'Chief Scientific Officer', 'pay': '418.23k', 'exercised': 'N/A', 'age': '52'}","{'name': 'Ms. Nadya  Lawrence', 'title': 'Sr. VP of Technical Services', 'pay': 'N/A', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Martin  Wilson', 'title': 'Gen. Counsel', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
TOCA,Tocagen Inc.,http://www.tocagen.com,N/A,N/A,N/A,"Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companys lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.","{'name': 'Mr. Martin J. Duvall', 'title': 'CEO & Director', 'pay': '86.16k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Harry E. Gruber M.D.', 'title': 'Co-Founder, Pres of Science & Innovation and Director', 'pay': '356.55k', 'exercised': 'N/A', 'age': '65'}","{'name': 'Dr. Asha  Das M.D.', 'title': 'Sr. VP & Chief Medical Officer', 'pay': '321.07k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Douglas J. Jolly Ph.D.', 'title': 'Co-Founder and Exec. VP of Research & Pharmaceutical Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '70'}","{'name': 'Mr. Mark G. Foletta CPA', 'title': 'Exec. VP & CFO', 'pay': 'N/A', 'exercised': 'N/A', 'age': '57'}"
TSRO,"Tesaro, Inc.",http://www.tesarobio.com,N/A,N/A,N/A,"Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. The company is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in pre-clinical research stage targeting lymphocyte-activation gene-3. It has license and collaboration agreements with AnaptysBio, Inc.; and The University of Texas MD Anderson Cancer Center, as well as with Janssen Biotech, Inc., Zai Lab (Shanghai) Co., Ltd, and OPKO Health, Inc. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.","{'name': 'Mr. Leon O. Moulder Jr., M.B.A.', 'title': 'Co-Founder, Chief Exec. Officer and Director', 'pay': '1.09M', 'exercised': 'N/A', 'age': '60'}","{'name': 'Dr. Mary Lynne Hedley Ph.D.', 'title': 'Co-Founder, Pres, Chief Operating Officer and Director', 'pay': '1.01M', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Timothy R. Pearson', 'title': 'Chief Financial Officer and Exec. VP', 'pay': '646.76k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Jeffrey H. Hanke Ph.D.', 'title': 'Chief Scientific Officer and Exec. VP of R&D', 'pay': '703.97k', 'exercised': '862.44k', 'age': '60'}","{'name': 'Dr. Martin H. Huber Jr., M.D.', 'title': 'Chief Medical Officer and Sr. VP', 'pay': '732.52k', 'exercised': 'N/A', 'age': '57'}"
TTPH,"Tetraphase Pharmaceuticals, Inc.",http://www.tphase.com,N/A,N/A,N/A,"Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a second-generation Gram-negative program, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. In addition, the company is involved in the discovery and development of additional antibiotics for the treatment of unmet medical needs, including multidrug-resistant Gram-negative bacteria. Tetraphase Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Watertown, Massachusetts.","{'name': 'Mr. Guy  MacDonald B.Sc', 'title': 'CEO, Pres & Director', 'pay': '724.1k', 'exercised': '76.73k', 'age': '58'}","{'name': 'Dr. Jacques  Dumas Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '508.56k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Ms. Maria D. Stahl', 'title': 'Sr. VP & Gen. Counsel', 'pay': '456.56k', 'exercised': 'N/A', 'age': '46'}","{'name': 'Dr. Patrick T. Horn M.D., Ph.D.', 'title': 'Chief Medical Officer', 'pay': '532.12k', 'exercised': 'N/A', 'age': '62'}","{'name': 'Ms. Kamalam  Unninayar', 'title': 'Chief Financial Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
TXMD,"TherapeuticsMD, Inc.",http://www.therapeuticsmd.com,N/A,N/A,N/A,"TherapeuticsMD, Inc. operates as a womens health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","{'name': 'Mr. Robert G. Finizio', 'title': 'Co-Founder, Chief Exec. Officer and Director', 'pay': '1.26M', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. John C. K. Milligan IV', 'title': 'Pres, Sec. and Director', 'pay': '784.08k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Brian A. Bernick M.D., F.A.C.O.G.', 'title': 'Co-Founder, Chief Clinical Officer and Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '50'}","{'name': 'Mr. Daniel A. Cartwright', 'title': 'Chief Financial Officer and Treasurer', 'pay': '651.57k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Mitchell L. Krassan', 'title': 'Chief Strategy Officer and Exec. VP', 'pay': '465.61k', 'exercised': 'N/A', 'age': '52'}"
USD,ProShares Ultra Semiconductors,N/A,N/A,N/A,N/A,N/A,,,,,
UTHR,United Therapeutics Corporation,http://www.unither.com,Healthcare,Drug Manufacturers - Other,750,"United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The companys product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.","{'name': 'Dr. Martine A. Rothblatt Ph.D., J.D., M.B.A.', 'title': 'Founder, Chairman & CEO', 'pay': '2.23M', 'exercised': '16.5M', 'age': '62'}","{'name': 'Mr. Michael I. Benkowitz', 'title': 'Pres & COO', 'pay': '1.27M', 'exercised': 'N/A', 'age': '45'}","{'name': 'Mr. James C. Edgemond', 'title': 'CFO & Treasurer', 'pay': '972.46k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Paul A. Mahon J.D.', 'title': 'Exec. VP, Gen. Counsel & Corp. Sec.', 'pay': '1.38M', 'exercised': 'N/A', 'age': '53'}","{'name': 'Dr. Roger A. Jeffs Ph.D.', 'title': 'Sr. Advisor', 'pay': '6.52M', 'exercised': 'N/A', 'age': '55'}"
VCYT,"Veracyte, Inc.",http://www.veracyte.com,N/A,N/A,N/A,"Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The companys products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.","{'name': 'Ms. Bonnie H. Anderson', 'title': 'Co-Founder, Chairman and Chief Exec. Officer', 'pay': '792.5k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Christopher M. Hall', 'title': 'Pres and Chief Operating Officer', 'pay': '572.75k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Mr. Keith S. Kennedy CFA, CPA', 'title': 'Chief Financial Officer', 'pay': '28.98k', 'exercised': 'N/A', 'age': '48'}","{'name': 'Dr. Giulia C. Kennedy Ph.D.', 'title': 'Chief Scientific Officer and Sr. VP of Research, Product & Clinical Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': '59'}","{'name': 'Mr. Ashish  Kheterpal', 'title': 'Chief Information Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
VNDA,Vanda Pharmaceuticals Inc.,http://www.vandapharmaceuticals.com,N/A,N/A,N/A,"Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companys marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.","{'name': 'Dr. Mihael H. Polymeropoulos M.D.', 'title': 'Founder, Chief Exec. Officer, Pres and Director', 'pay': '2.13M', 'exercised': 'N/A', 'age': '57'}","{'name': 'Mr. James Patrick Kelly C.F.A.', 'title': 'Chief Financial Officer, Exec. VP and Treasurer', 'pay': '625.23k', 'exercised': 'N/A', 'age': '51'}","{'name': 'Mr. Richard L. Gulino', 'title': 'Sr. VP, Gen. Counsel and Sec.', 'pay': '544.9k', 'exercised': 'N/A', 'age': '54'}","{'name': 'Mr. Gian Piero Reverberi', 'title': 'Chief Commercial Officer and Sr. VP', 'pay': '717.87k', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Mr. Gunther  Birznieks', 'title': 'Sr. VP of Bus. Devel.', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
VRTX,Vertex Pharmaceuticals Incorporated,http://www.vrtx.com,Healthcare,Biotechnology,"2,150","Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.","{'name': 'Dr. Jeffrey M. Leiden M.D., Ph.D.', 'title': 'Chairman, Chief Exec. Officer and Pres', 'pay': '3.56M', 'exercised': 'N/A', 'age': '61'}","{'name': 'Mr. Ian F. Smith CPA, ACA', 'title': 'COO & Exec. VP', 'pay': '1.33M', 'exercised': 'N/A', 'age': '51'}","{'name': 'Dr. David M. Altshuler M.D., Ph.D.', 'title': 'Chief Scientific Officer and Exec. VP of Global Research', 'pay': '1.07M', 'exercised': 'N/A', 'age': '52'}","{'name': 'Mr. Michael J. Parini J.D.', 'title': 'Chief Legal & Admin. Officer and Exec. VP', 'pay': '1.31M', 'exercised': 'N/A', 'age': '42'}","{'name': 'Mr. Amit K. Sachdev J.D.', 'title': 'Exec. VP & Chief Regulatory Officer', 'pay': '979.72k', 'exercised': 'N/A', 'age': '49'}"
VTL,"Vital Therapies, Inc.",http://vitaltherapies.com,N/A,N/A,N/A,"Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patients own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.","{'name': 'Dr. Terence  E. Winters BSc, Ph.D.', 'title': 'CEO & Director', 'pay': '582.31k', 'exercised': 'N/A', 'age': '76'}","{'name': 'Dr. Duane  Nash M.D., J.D., M.B.A', 'title': 'Pres', 'pay': '443.37k', 'exercised': 'N/A', 'age': '47'}","{'name': 'Mr. Robert A. Ashley M.A.', 'title': 'Chief Technical Officer and Exec. VP', 'pay': '453.53k', 'exercised': 'N/A', 'age': '60'}","{'name': 'Mr. Michael V. Swanson M.B.A', 'title': 'Chief Financial Officer, Exec. VP and Treasurer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '63'}","{'name': 'Mr. Aron P. Stern M.B.A.', 'title': 'Chief Admin. Officer', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}"
VYGR,"Voyager Therapeutics, Inc.",http://www.voyagertherapeutics.com,,,77,"Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The companys lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntingtons disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, Alzheimers disease; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","{'name': 'Dr. Steven M. Paul M.D.', 'title': 'Chief Exec. Officer, Pres and Director', 'pay': '745.95k', 'exercised': 'N/A', 'age': '66'}","{'name': 'Dr. Dinah  Sah Ph.D.', 'title': 'Chief Scientific Officer', 'pay': '430.04k', 'exercised': 'N/A', 'age': '56'}","{'name': 'Dr. Robert G. Pietrusko Pharm. D.', 'title': 'Sr. VP of Regulatory Affairs & Quality Assurance', 'pay': '496.03k', 'exercised': 'N/A', 'age': '69'}","{'name': 'Dr. Krystof  Bankiewicz M.D., Ph.D.', 'title': 'Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}","{'name': 'Dr. Guangping  Gao Ph.D.', 'title': 'Founder', 'pay': 'N/A', 'exercised': 'N/A', 'age': 'N/A'}"
XLRN,Acceleron Pharma Inc.,http://www.acceleronpharma.com,Healthcare,Biotechnology,121,"Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companys therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.","{'name': 'Mr. Habib J. Dable', 'title': 'Pres, CEO & Director', 'pay': '472.76k', 'exercised': 'N/A', 'age': '49'}","{'name': 'Dr. Thomas P. Maniatis Ph.D.', 'title': 'Co-Founder, Member of Scientific Advisory Board & Director', 'pay': '40k', 'exercised': 'N/A', 'age': '75'}","{'name': 'Mr. Kevin F. McLaughlin', 'title': 'Chief Financial Officer, Sr. VP and Treasurer', 'pay': '522.36k', 'exercised': '608.21k', 'age': '62'}","{'name': 'Dr. Ravindra  Kumar Ph.D.', 'title': 'Chief Scientific Officer and Sr. VP', 'pay': '486.25k', 'exercised': '1.37M', 'age': '58'}","{'name': 'Dr. Matthew L. Sherman M.D.', 'title': 'Chief Medical Officer and Exec. VP', 'pay': '605.43k', 'exercised': '1.38M', 'age': '62'}"
XNCR,"Xencor, Inc.",http://www.xencor.com,Healthcare,Biotechnology,83,"Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companys product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.","{'name': 'Dr. Bassil I. Dahiyat Ph.D.', 'title': 'Co-Founder, Chief Exec. Officer, Pres and Director', 'pay': '761.61k', 'exercised': '5.14M', 'age': '47'}","{'name': 'Mr. John J. Kuch', 'title': 'VP of Fin. and Sec.', 'pay': '434.18k', 'exercised': '984.34k', 'age': '58'}","{'name': 'Dr. John R. Desjarlais Ph.D.', 'title': 'Chief Scientific Officer and Sr. VP of Research', 'pay': '491.68k', 'exercised': '3.47M', 'age': '53'}","{'name': 'Dr. Edgardo  Baracchini Jr., Ph.D., M.B.A.', 'title': 'Chief Bus. Officer', 'pay': '394.46k', 'exercised': '591.76k', 'age': '58'}","{'name': 'Dr. Paul A. Foster M.D., F.A.H.A.', 'title': 'Chief Medical Officer and Sr. VP', 'pay': '602.33k', 'exercised': '84.55k', 'age': '63'}"
ZGNX,"Zogenix, Inc.",http://www.zogenix.com,N/A,N/A,N/A,"Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The companys lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.","{'name': 'Dr. Stephen J. Farr Ph.D.', 'title': 'Co-Founder, CEO, Pres & Director', 'pay': '677.89k', 'exercised': 'N/A', 'age': '58'}","{'name': 'Mr. Roger L. Hawley', 'title': 'Co-Founder & Director', 'pay': 'N/A', 'exercised': 'N/A', 'age': '64'}","{'name': 'Dr. Bradley S. Galer M.D.', 'title': 'Exec. VP & Chief Medical Officer', 'pay': '510.23k', 'exercised': 'N/A', 'age': '55'}","{'name': 'Dr. Gail M. Farfel Ph.D.', 'title': 'Exec. VP & Chief Devel. Officer', 'pay': '477.06k', 'exercised': 'N/A', 'age': '53'}","{'name': 'Ms. Ann D. Rhoads', 'title': 'Consultant', 'pay': '498.27k', 'exercised': 'N/A', 'age': '52'}"
